IRB Protocol Number:  2019C0145  
IRB Approval date:  06/10/2022  
Version:  05/06/2022  
 
PROTOCOL NUMBER: OSU-[ZIP_CODE]        
   
 Page i CLINICAL STUDY PROTOCOL  
 
AN INVESTIGATOR- SPONSORED PHASE 2  SINGLE ARM TRIAL  OF 
RAMUCIRUMAB  AND PEMBROLIZUMAB  IN PATIENTS WITH EGFR MUTANT 
NON- SMALL CELL LUNG CANCER  
 
PROTOCOL NUMBER: 
  OSU -[ZIP_CODE]  
PROTOCOL VERSION:  1.9 
PROTOCOL VERSION DATE:  05/06 /[ADDRESS_587003]:  RAMUCIRUMAB  
PEMBROLIZUMAB 
SPONSORING PRINCIPAL 
INVESTIGATOR:  [INVESTIGATOR_459672], MBBS   
DRUG PRODUCT SUPPLIER:  LILLY  
MERCK  
  
  
  
  
  
  
   
  
  
STATISTICIAN:  SARAH JANSE , PHD  
 
 
IRB Protocol Number:  2019C0145  
IRB Approval date:  06/10/2022  
Version:  05/06/2022  
 
PROTOCOL NUMBER: OSU-[ADDRESS_587004] be informed that the information is privileged or confidential and may not be disclosed by [CONTACT_476]. These restrictions on disclosure will apply equally to all future information supplied to you, which is indicated as privileged or confidential. 
  
IRB Protocol Number:  2019C0145  
IRB Approval date:  06/10/2022  
Version:  05/06/2022  
 
PROTOCOL NUMBER: OSU-[ADDRESS_587005] OF ABBREVIATIONS AND DEFINITIONS OF TERMS  ........................................ xiv 
1. Introduction ........................................................................................................................... 1 
1.1 Overview  ......................................................................................................................... 1 
1.2 Ramucirumab:  Mechanism of Action  ......................................................................... 1 
1.3 Pembrolizumab:  Mechanism of Action  ....................................................................... 2 
1.3.1 Clinical Experience  ................................................................................................... 2 
1.4 Clinical Safety  ................................................................................................................. 3 
1.5 Phase II Single Arm Trial of Ramucirumab and Pembrolizumab in EGFR mutant 
Non-Small Cell Lung Cancer  ................................................................................................... 3 
2. Objectives and Endpoints  ..................................................................................................... 8 
2.1 Primary Objective  .......................................................................................................... 8 
Primary Endpoint:  .................................................................................................................... 8 
2.2 Secondary Objectives  ..................................................................................................... 8 
Secondary Endpoints  ................................................................................................................ 8 
2.3 Exploratory objectives ................................................................................................... 9 
3. Investigational Plan ............................................................................................................... 9 
3.1 Overview of Study Design and Dosing Regimen ......................................................... 9 
3.1.1 Definition of Treatment Cycle and Duration .......................................................... 10 
3.1.3 Treatment Phase  ...................................................................................................... 10 
3.1.4 End of Treatment Visit............................................................................................ 10 
3.2 Study Duration  ............................................................................................................. 10 
3.3 Study Schema  .................................................................................................................... 12 
4.
 Patient Selection  ................................................................................................................... 13 
4.1 Study Population and Sample Size  ............................................................................. 13 
4.2 Inclusion Criteria  ......................................................................................................... 13 
4.3 Exclusion Criteria  ........................................................................................................ 15 
4.4 Lifestyle Restrictions  .................................................................................................... 17 
Pregnancy  .............................................................................................................................. 17 
Use in Nursing Women ......................................................................................................... 18 
4.5 Patient Removal from Study ....................................................................................... 18 
5. Investigational Medicinal Products and treatment plan .................................................. 19 
5.1 Ramucirumab Formulation and Administration ...................................................... 19 
5.2 Ramucirumab Storage and Stability  .......................................................................... 19 
5.3 Ramucirumab Labelling  ................................................................
.............................. 19 
5.4 Ramucirumab Dosing Information ............................................................................ 19 
5.5 Pembrolizumab Formulation and Administration ................................................... 20 
5.6 Pembrolizumab Storage and Stability  ....................................................................... 20 
5.7 Pembrolizumab Labelling  ........................................................................................... 20 
IRB Protocol Number:  2019C0145  
IRB Approval date:  06/10/2022  
Version:  05/06/2022  
 
PROTOCOL NUMBER: OSU-[ZIP_CODE]        
   
 Page iv 5.8 Pembrolizumab Dosing Information .......................................................................... 20 
5.9 Handling – Ramucirumab and Pembrolizumab  ....................................................... [ADDRESS_587006] Accountability  .................................................................................. 21 
6. Study Procedures  ................................................................................................................. 22 
6.1 Study Assessments  ........................................................................................................ 22 
6.1.1 Efficacy Assessments .............................................................................................. 22 
6.1.2 Laboratory Assessments ......................................................................................... 22 
6.1.3 Sample Collection for translational analyses ................................................................ 23 
6.2 Data Safety and Monitoring Plan ............................................................................... 25 
6.3 Schedule of Study Events  ............................................................................................. 25 
6.4 End of Study  ................................................................................................................. 32 
6.5 Planned Treatment of the Patients after End of Treatment Phase  ......................... 32 
6.6 Removal of Patients from Treatment  ......................................................................... 32 
6.7 Study Discontinuation  .................................................................................................. 33 
7. Toxicities, Risks and AE-Related Dose Modifications ..................................................... 33 
7.1 Ramucirumab Toxicity Overview ............................................................................... 33 
7.2 Pembrolizumab Toxicity Overview  ............................................................................ 35 
8. Supportive Care Guidelines  ................................................................................................ 43 
8.1 Concomitant Medications ............................................................................................ 43 
8.2 Permitted Concomitant Medication  ........................................................................... 43 
8.3 Glucocorticoid therapy  ................................................................................................ 43 
8.4 Prohibited Medication  ................................................................................................. 43 
8.5 Rescue Medications & Supportive Care  .................................................................... 44  
8.6 Dose Adjustments for Weight  ..................................................................................... 44 
9. Statistical Considerations .................................................................................................... 45 
9.1 Endpoints  ...................................................................................................................... 45 
9.1.1 Primary Endpoint .................................................................................................... 45 
9.1.2 Secondary Endpoints .............................................................................................. 45 
9.2 Sample Size Justification  ............................................................................................. 45 
9.3 Planned Interim Analysis  ............................................................................................ 45 
9.4 Analysis Plan ................................................................................................................. 45 
9.4.1 Primary endpoint analysis: ...................................................................................... 45 
9.4.2 Analysis of secondary endpoints: ........................................................................... 46 
9.5 Analysis of Exploratory Endpoints - Correlative studies:  ........................................ 48 
10.
 Data Management ............................................................................................................ 49 
10.1 Clinical Data  .............................................................................................................. 49 
10.2 Quality Assurance ..................................................................................................... 49 
11. Protection of Human Subjects  ........................................................................................ 49 
11.1 Human Subjects Involvement and Characteristics:  .............................................. 49 
11.2 Consent process:  ....................................................................................................... 50 
11.3 Possible Toxicities/Side -Effects:  .............................................................................. 50 
11.3.1 Benefits  ................................................................................................................... 50 
IRB Protocol Number:  2019C0145  
IRB Approval date:  06/10/2022  
Version:  05/06/2022  
 
PROTOCOL NUMBER: OSU-[ZIP_CODE]        
   
 Page v 11.3.2 Costs ........................................................................................................................ 50 
11.3.3 Alternatives  ............................................................................................................. 50 
11.3.4 Confidentiality  ........................................................................................................ 50 
11.3.5 Patient safety  ........................................................................................................... 50 
11.3.6 Monitoring of data to ensure safety ........................................................................ 51 
11.3.7 Privacy  .................................................................................................................... 51 
12. Informed Consent  ............................................................................................................ 51 
13. Reporting Requirements  ................................................................................................. 51 
13.1 Adverse Drug Reaction Reporting  .......................................................................... 51 
13.2 Serious Adverse Event Reporting (SAE)  ................................................................ 52 
13.3 Reporting to FDA:  .................................................................................................... 53 
13.4 Reporting to the Drug Provider (Lilly)  ................................................................... 53 
13.5 Reporting to the Drug Provider (Merk)  ................................................................. 54 
13.6 Sponsor Responsibility for Reporting Adverse Events  ......................................... 57 
14. References  ......................................................................................................................... 58 
Contraception Requirements ................................................................................................. 68 
Pregnancy Testing ................................................................................................................. 70 
  
IRB Protocol Number:  2019C0145  
IRB Approval date:  06/10/2022  
Version:  05/06/2022  
 
PROTOCOL NUMBER: OSU-[ZIP_CODE]        
   
 Page vi SYNOPSIS  
 
Study Title  A Phase II Single Arm Trial of Ramucirumab with 
Pembrolizumab in EGFR M utant Non- Small Cell Lung 
Cancer  
Study Rationale  Non-small cell lung cancer (NSCLC) is one of the most 
common and lethal cancers in the [LOCATION_002]. Fifteen 
percent of these NSCLC pa tients have epi[INVESTIGATOR_8199] (EGFR) driver mutations, which are 
associated with high response rates (>70%) to tyrosine 
kinase inhibitors (TKI) but low response rates (10%) to 
single agent immune checkpoint inhibitors (ICI) such as 
pembroliz umab (anti -PD1 monoclonal antibody (mAb)).[ 1-
5] In addition, response s to TKIs are not durable due to 
acquired resistance. [6] Vascular endothelial growth factor 
(VEGF) has emerged as a potential pathway of interest for 
treatment in this patient population because EGFR mutant 
NSCLC is as sociated with increased VEGF expression. [7] 
Notably, VEGF induces tumor related angiogenesis and also has immune dysregulatory effects that impact dendritic cell (DC) maturation, myeloid derived suppressor cells ( MDSC) 
proliferation, and T cell PD -1 expression.[ 8-11
] In clinical 
and preclinical studies, VEGFR inhibitors reverse this 
immune dysregulation and may work in synergy with ICI to 
enhance i mmune response.[ 12-14]  
Give n the lack of durable responses to first line therapy in 
EGFR mutant NSCLC, development of tolerable and 
effective second line therapi[INVESTIGATOR_47629]. Two phase 3 
trials demonstrated potential clinical importance of VEGF 
inhibitors for EGFR mutant patient s receiving ICI. 
IMPower150 demonstrated progression- free survival 
advantage for carboplatin and paclitaxel with bevacizumab (anti-VEGF mAb) and atezolizumab (anti -
PDL1 mAb) 
whereas IMPower130 demonstrated no survival difference for carboplatin, nab- paclit
axel, and atezolizumab without 
the addition of bevacizumab.[ 15-17 ] These results suggest a 
key role of anti -VEGF in combination with ICI in the EGFR 
mutant population and this combination may obviate the 
need for chemotherapy. Chemotherapy toxicity was 
significant in both IMPower trials – up to 55% of patients 
experienced grade 3- [ADDRESS_587007] of which was 
attributable to carboplatin and paclitaxel (neuropathy, 
nausea, and pancytopenia).[ 16] 
IRB Protocol Number:  2019C0145  
IRB Approval date:  06/10/2022  
Version:  05/06/2022  
 
PROTOCOL NUMBER: OSU-[ZIP_CODE]        
   
 Page vii To evaluate the clinical efficacy of this co mbination, we 
propose a phase II single arm trial of ramucirumab (anti -
VEGFR mAb) and pembrolizumab (anti -PD1 mAb) for 
EGFR mutant NSCLC patients who have progressed on at least one EGFR TKI. The primary endpoint will be response rate and the secondary end points will be safety, tolerability, 
and survival. We anticipate that the combination of 
ramucirumab and pembrolizumab will be associated with a higher response rate (≥ 25%) than observed responses with single agent ICI (~ 10%). We will perform exploratory  
correlative studies to evaluate the immune cell activation 
profiles with combination therapy. 
Primary Objective  To evaluate response rate of the combination of 
ramucirumab  and pembrolizumab in EGFR mutant 
NSCLC.  
Secondary 
Objectives  
 
Correlative Studies  
 
 To evaluate safety, tolerability, and survival for patients 
receiving ram ucirumab and pembrolizumab.  
 
Exploratory objectives: To characterize predictive 
immunologic biomarkers of response in tissue and 
peripheral blood of patients receiving R+P combination 
therapy  
 
Exploratory Correlative Endpoints: 
1) Baseline tumor immunoprofile by [CONTACT_4658], including tumor 
infiltrating lymphocytes and T cell receptor (TCR) 
immunosequencing (immunoSEQ) and relationship to 
clinical outcomes, in cluding response rate.  
2)  C irculating immune cell profiles in response to treatment 
and in relation to clinical response using 10- color 65 marker 
multiplex CyTOF  profile on peripheral blood samples. 
3) Circulating VEGF at baseline, after treatment and at  
progression to evaluate correlation with clinical response. 
 
Sample Size  Minimum 13 patients, maximum 34 patients  
Study Design  Agents:  Ramucirumab, Pembrolizumab  
IRB Protocol Number:  2019C0145  
IRB Approval date:  06/10/2022  
Version:  05/06/2022  
 
PROTOCOL NUMBER: OSU-[ZIP_CODE]        
   
 Page viii Tumor type : EGFR mutation positive NSCLC  
The proposed study will be an open- label single arm phase 
II trial of ramucirumab and pembrolizumab (R+P) in EGFR 
mutant NSCLC after progression on tyrosine kinase 
inhibitors (TKIs) . Patients are required to receive at least one 
TKI (erlotinib, gefitinib, afatinib or osimertinib).  Post- TKI 
chemotherapy is also permitted.  
Each treatment cycle will be 21 days; patients will receive ramucirumab 10 mg/kg IV and pembrolizumab 200 mg IV and on day 1. Dosing of ramucirumab and pembrolizumab 
is based on prior phase 1 testing of the combination. A two-
stage design will be utilized to minimize exposure to 
combination therapy if there is limited efficacy. The initial stage will enroll 13 patients; if  ≥ [ADDRESS_587008] (RECIST 1.[ADDRESS_587009]). Imaging will be performed every 6 weeks/2 
cycles to assess response. Patients with clinical benefit may continue therapy beyond progression for up to 2 cycles – if 
progressive disease confirmed on repeat imaging, therapy 
would be discontinued. Toxicity will be assessed using 
CTCAE v 5.0. Progression free survival will be assessed 
using RECIST and will be assessed starting from date of  
study enrollment. 
Blood samples tissue will be collected at baseline (day 1, 
cycle 1), cycle 3 day1 (approx. 6 weeks), and at study 
discontinuation ( or progression). Archival tissue will be 
requested at enrollment for correlative studies .  
Duration of 
Treatment  Patients may continue to receive study treatment (R+P)   
until radiographic documentation of disease progression, the occurrence of unacceptable toxicity or of the occurrence of other withdrawal criteria.   
 If either drug is discontinued due to toxicity, the other drug may be continued.  
 
Inclusion /Exclusion 
Criteria  Inclusion Criteria:  
1. Adult patients age d ≥18 years  
IRB Protocol Number:  2019C0145  
IRB Approval date:  06/10/2022  
Version:  05/06/2022  
 
PROTOCOL NUMBER: OSU-[ZIP_CODE]        
   
 Page ix 2. Histologically confirmed recurrent or metastatic non -
small cell carcinoma of the lung with sensitizing EGFR 
mutations. Exon 20 resistance mutations will not be 
permitted but uncommon sensitizing mutations are 
allowed.  
3. Prior Systemic Anticancer Therapy: Neo/adjuvant 
therapy or prior therapy for locally advanced disease 
will be permitted. Patients with prior exposure to 
PD/PD -L1 inhibitors will be excluded. No limit on  prior 
EGFR TKIs (e rlotinib, gefitinib, afatinib, dacomitinib 
or osimertinib). Prior chemotherapy for metastatic 
disease is permitted only. A [ADDRESS_587010] be postmenopausal, surgically sterile, or using effective contraception (hormonal or barrier methods).  
8. Female patients of childbearing potential must have a negative serum pregnancy test within [ADDRESS_587011] 2 years (i.e. with use of disease 
modifying agents, corticosteroids or 
immunosuppressive drugs). Replacement therapy (eg., 
thyroxine, insulin, or physiologic corticosteroid 
replacement therapy for adrenal or pi[INVESTIGATOR_12978], etc.) is not considered a form of systemic 
treatment.  
2. Known active chronic infections – HIV/AIDS, known 
active Hepatitis B or C. K nown history of Hepatitis B 
(defined as Hepatitis B surface antigen [HBsAg] 
reactive) or known active Hepatitis C virus (defined as 
HCV RNA [ qualitative]  is detected) infection. Note: no 
IRB Protocol Number:  2019C0145  
IRB Approval date:  06/10/2022  
Version:  05/06/2022  
 
PROTOCOL NUMBER: OSU-[ZIP_CODE]        
   
 Page x testing for Hepatitis B and Hepatitis C is required unless 
mandated by [CONTACT_14306].  
3. Cirrhosis (Child -Pugh B or worse) or cirrhosis with 
history of hepatic encephalopathy or clinically meaningful ascites resulting from cirrhosis.  
4. Prior exposure to ramucirumab. 
5. H
as received prior therapy with an anti -PD-1, anti- PD-
L1, or anti- PD-L2 agent or with an agent directed to 
another stimulatory or co-inhibitory T- cell receptor 
(eg, CTLA -4, OX-40, CD137). 
6. A ny Grade [ADDRESS_587012] dose of protocol therapy. 
7. History of deep vein thrombosis (DVT), pulmonary embolism (PE), or any other significant thromboembolism (venous port or catheter thrombosis or superficial venous thrombosis are not considered “significant”) during the [ADDRESS_587013] dose of protocol therapy. 
8. Patients receiving dipyridamole, clopi[INVESTIGATOR_7745], or similar agents. Once -daily aspi[INVESTIGATOR_34308] (maximum dose 
325 mg/day) is permitted.  
9. Uncontr olled  CNS metastases. Patients with treated 
brain metastases are eligible if they were clinically stable with regard to neurologic function, off steroids after cranial irradiation (whole brain radiation therapy, focal radiation therapy, and stereotactic radiosurgery) ending at least [ADDRESS_587014] no evidence of Grade ≥[ADDRESS_587015] scan (performed within [ADDRESS_587016] dose of study treatment). Note:  Patients who received systemic 
therapy that adequately and appropriately treated CNS metastases, including tyrosine kinase inhibitors, are eligible provided that CNS disease control is confirmed by [CONTACT_459686] [ADDRESS_587017] dose of study treatment. 
10. H
emoptysis (defined as bright red blood or 
≥ 1/2 teaspoon) within [ADDRESS_587018] dose of 
protocol therapy or with radiographic evidence of 
intratumor cavitation or has radiologically documented evidence of major blood vessel invasion or encasement 
by [CONTACT_67380].  
IRB Protocol Number:  2019C0145  
IRB Approval date:  06/10/2022  
Version:  05/06/2022  
 
PROTOCOL NUMBER: OSU-[ZIP_CODE]        
   
 Page xi 11. Uncontrolled or poorly -controlled hypertension (>160 
mmHg systolic or > 100 mmHg diastolic for >4 weeks) despi[INVESTIGATOR_328784].  
12. Any arterial thromboembolic events, including but not limited to myocardial infarction, transient isch emic 
attack, cerebrovascular accident, or unstable angina, within [ADDRESS_587019] dose of protocol therapy.  Patient has elective or planned major surgery to be performed during the course of the clinical trial. 
14. Serious or non-healing wound, ulcer, or bone fracture within 28 days of study treatment.  
15. Prior history of GI perforation/fistula (within [ADDRESS_587020] dose of protocol therapy) or risk factors for perforation. 
16. Small cell or mixed (small cell/non -small cell) lung 
cancer  
17. Pregnancy or breastfeeding.  
18. Has received a live vaccine within [ADDRESS_587021] dose of study drug.  Examples of live vaccines include, but are not limite d to, the following:  measles, 
mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette –Guérin (BCG), and 
typhoid vaccine.  Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; howeve r, intranasal influenza vaccines 
(eg, FluMist®) are live attenuated vaccines and are not 
allowed.  
19. History of (non-infectious) pneumonitis that required steroids or has current pneumonitis. 
20. History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject’s participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opi[INVESTIGATOR_80021].   
21. Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.  
22. Severe hypersensitivity (≥Grade 3) to pembrolizumab 
and/or any of its excipi[INVESTIGATOR_840]. 
23. Active infection requiring systemic therapy. 
24. Known history of active TB   (Bacillus Tuberculosis).   
 
IRB Protocol Number:  2019C0145  
IRB Approval date:  06/10/2022  
Version:  05/06/2022  
 
PROTOCOL NUMBER: OSU-[ZIP_CODE]        
   
 Page xii   
Screening 
Assessments Signed written informed consent   
Inclusion/Exclusion Criteria   
Demographics and medical history  
Pregnancy test (if applicable)  Physical examination , ECOG,  and vital signs  
Urine analysis  
Hematology (CBC, coagulation studies) Complete serum chemistry  
Assessment o f disease status  
Concomitant medication   
Treatment and Post -
Treatment 
Assessments Cycle 1 , Day 1  
Physi cal examination and vital signs  
Complete b lood count with differential 
Complete clinical chemistry ( including liver function tests) 
TSH  - free T3 and T4 if abnormal 
Adverse events and concomitant medication  Cycle 1, Day 8 Physical examination and vital signs  Complete clinical chemistry (including liver function tests) Urinalysis   Cycle 2 and Beyond Physical examination and vital signs Complete blood count with differential Complete clinical chemistry (including liver function tests)  
TSH  - free T3 and T4 if abnormal – repeat every [ADDRESS_587022] (if applicable)   Assessment of disease status:  
• CT scans  (disease evaluation will be done 
according to irRECIST and RECIST 1.1)  
 
Adverse events and concomitant medication 
IRB Protocol Number:  2019C0145  
IRB Approval date:  06/10/2022  
Version:  05/06/2022  
 
PROTOCOL NUMBER: OSU-[ZIP_CODE]        
   
 Page xiii  
Final Visit  
Physical examination and vital sign s 
Complete blood count with differential 
Complete clinical chemistry (including liver function tests)  
Assessment of disease status 
Adverse events and concomitant medication 
Response  CT scan s will be used for tumor assessment, at 
baseline and then at 6 week intervals. Patients who achieve 
stable disease, partial response ( PR), or complete response 
(CR) per RECIST v.1.[ADDRESS_587023] will be discontinued.  
Safety Variables & 
Analysis  The safety and tolerability of ramucirumab and 
pembrolizumab will be evaluated by [CONTACT_459687] , adverse event ( AE) reports, physical 
examinations, and laboratory safety evaluations. Common Terminology Criteria f or Adverse Events (CTCAE) v5.0 
will be used for grading of AEs.  Investigators will provide their assessment of causality as 1) unrelated, 2) possibly related,  or 3) probably or definitely related for all AEs.   
Statistical Analysis
  The primary study objective is to assess the overall response 
rate (ORR) of ramucirumab and pembrolizumab. The study 
will use Simon’s two -stage design. Response rate with 
single ag ent IO is around 10% and we would consider a 
response rate of at least 25% to be interesting for further 
study. The initial stage will include 13 patients; the trial will 
be terminated if there are no responses. If the trial goes on to the second stage, an 
additional [ADDRESS_587024]. Estimates from this analysis 
will be used as preliminary da ta to inform future research.  
 
 
IRB Protocol Number:  2019C0145  
IRB Approval date:  06/10/2022  
Version:  05/06/2022  
 
PROTOCOL NUMBER: OSU-[ADDRESS_587025]  Adverse Drug Reaction  
AE Adverse event  
ALT (SGPT)  Alanine aminotransferase  
ANC  Absolute neutrophil count  
APC  Adenomatous polyposis coli  
API [INVESTIGATOR_459673] (SGOT)  Aspartate aminotransferase  
AUC  Area under the curve  
BMI  Body mass index  
BSA  Body surface area  
BUN  Blood urea nitrogen  
BW Body weight  
CBC  Complete blood count  
CI Confidence interval  
CK Creatine kinase  
CNS  Central nervous system  
CR Complete response  
CRF  Case report form  
CRO  Contract research organisation  
CTCAE  Common terminology criteria for adverse events  
CT Scan  Computed Tomography Scan  
CYP450  Cytochrome P450  
DCR  Disease control rate  
DLT  Dose -limiting toxicity  
DNA  Desoxyribonucleic acid  
ECG  Electrocardiogram  
ECOG  Eastern Cooperative Oncology Group  
EOT  End of treatment  
FU Follow -up 
GCP  Good Clinical Practice  
GI Gastrointestinal  
GLP  Good laboratory practice  
h Hour  
HR Hazard ratio 
IA Interim analysis  
IMP Investigational medicinal product  
INR International normalized ratio  
IRB Institutional review board  
ITT Intent to treat  
i.v. Intravenous  
KRAS  Kirsten Rat sarcoma  
LDH  Lactate dehydrogenase  
m² Square metre (body surface area)  
IRB Protocol Number:  2019C0145  
IRB Approval date:  06/10/2022  
Version:  05/06/2022  
 
PROTOCOL NUMBER: OSU-[ADDRESS_587026]  Serious adverse drug reaction  
S[LOCATION_003]R  Suspected unexpected serious adverse reaction  
TSH  Thyroid Stimulating Hormone  
TTP Time to progression  
UNL  Upper normal limit  
WBC  White blood cell count  
 
IRB Protocol Number:  2019C0145  
IRB Approval date:  06/10/2022  
Version:  05/06/2022  
 
PROTOCOL NUMBER: OSU-[ZIP_CODE]        
   
 Page 1 1. INTRODUCTION 
1.1 Overview   
Non-small cell lung cancer (NSCLC) is one of the most common and lethal cancers in the United 
States. Fifteen percent of these NSCLC patients have epi[INVESTIGATOR_3506] (EGFR) driver mutations, which are associated with high response rates (>70%) to tyrosine kinase inhibitors (TKI) but low response rates (10%) to single agent immune checkpoint inhibitors (ICI) such as p embrolizumab (anti -PD1 monoclonal antibody (mAb)).[ 1-5] In addition, response s to 
TKIs are not durable due to acquired resistance. [6] Vascular endothelial growth factor (VEGF) 
has emerged as a potential pathway of interest for treatment in this patient population because EGFR mutant NSCLC is as sociated with increased VEGF expression. [7] Notably, VEGF induces 
tumor related angiogenesis and also has immune dysregulatory effects that impact dendritic cell (DC) maturation, myeloid derived suppressor cells (MDSC) proliferation, and T cell PD -1 
expression.[ 8-11] In clinical and preclinical studies, VEGFR inhibitors reverse this immune 
dysregulation and may work in synergy with ICI to enhance immune response.[ 12-14]  
Given the lack of durable responses to first line therapy in EGFR mutant NSCLC, development of tolerable and effective second line therapi[INVESTIGATOR_47629]. Two phase 3 trials demonstrated potential clinical importance of VEGF inhibitors for EGFR mutant patients receiving ICI. IMPower150 demonstrated progression- free survival advantage for carboplatin and paclitaxel with 
bevacizumab (anti -VEGF mAb) and atezolizumab (anti -PDL1 mAb) whereas IMPower130 
demonstrated no survival difference for carboplatin, nab-paclitaxel, and atezolizumab without the addition of bevacizumab.[ 15-17] These results suggest a key role of anti -VEGF in combination 
with ICI in the EGFR mutant population and this  combination may obviate the need for 
chemotherapy. Chemotherapy toxicity was significant in both IMPower trials – up to 55% of 
patients experienced grade [ADDRESS_587027] of which was attributable to carboplatin and 
paclitaxel (neuropathy, nausea, and pancytopenia).[ 16] 
To evaluate the clinical efficacy of this combination, we propose a phase II single arm trial of ramucirumab (anti -VEGFR mAb) and pembrolizumab (anti -PD1 mAb) for EGFR mutant NSCLC 
patients who have progressed on at least one EGFR TKI. The primary endpoint will be response rate and the secondary endpoints will be safety, tolerability, and survival. We anticipate that the combination of ramucirumab and pembr olizumab will be associated with a higher response rate (≥ 
25%) than observed responses with single agent ICI (~ 10%). We will perform exploratory 
correlative studies to evaluate the immune cell activation profiles with combination therapy.  
1.2 Ramucirumab:  Mechanism of Action  
Ramucirumab  i
 s an anti -VEGFR -2 monoclonal antibody (mAb); it inhibits angiogenesis by 
[CONTACT_459688] -2 inhibiting binding of VEGF receptor 
ligands VEGF -A, VEGF -C, and VEGF -D. Clinical studies support the activity of ramucirumab in 
altering the tumor microenvironment; among other changes, PD -L1 expression and CD8+ T cell 
infiltration was increased with ramucirumab. [14] The relationship between tumor VEGF and PD-
1 pr
esents a critical therapeutic opportunity to target both pathways to enhance clinical response.  
IRB Protocol Number:  2019C0145  
IRB Approval date:  06/10/2022  
Version:  05/06/2022  
 
PROTOCOL NUMBER: OSU-[ZIP_CODE]        
   
 Page 2 1.3 Pembrolizumab:  Mechanism of Action  
Pembrolizumab  is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) 
with high specificity of binding to the programmed cell death 1 ( PD-1) receptor, thus inhibiting 
its interaction with programmed cell death ligand 1 (PD- L1) and programmed cell death  ligand 2 
(PD-L2).  Based on preclinical in vitro data, pembrolizumab has high affinity and potent receptor 
blocking activity for PD-1.  Pembrolizumab has an acceptable preclinical safety profile and is in clinical development as an intravenous (IV) immunotherapy for advanced malignancies.  Pembrolizumab (Keytruda
®) is indicated for the treatment of patients across a number of 
indications because of its mechanism of action to bind the PD-[ADDRESS_587028] immune surveillance function in controlling outgrowth of neoplastic 
transformations has been known for decades.[ 18]  Accumulating evidence shows a correlation 
between tumor-infiltrating lymphocytes in cancer tissue and favorable prognosis in various malignancies.  In particular, the presence of CD8+ T-cells and the ratio of CD8+ effector T-cells/FoxP3+ regulatory T- cells (T -regs) correlates with improved prognosis and long- term 
survival in solid malignancies, such as ovarian, colorectal, and pancreatic cancer; hepatocellular carcinoma; malignant melanoma; and renal cell carcinoma.  Tumor -infiltrating lymphocytes can 
be expanded ex vivo and reinfused, inducing durable objective tumor responses in cancers such as melanoma. [19, 20] 
The PD -[ADDRESS_587029] hijacked by [CONTACT_13207].  The normal function of PD- 1, expressed on the cell surface of activated T -cells under 
healthy conditions, is to down-modulate unwanted or excessive immune responses, including autoimmune reactions. PD-1 (encoded by [CONTACT_13228]1) is an immunoglobulin (Ig) superfamily member related to cluster of differentiation 28 (CD28) and cytotoxic T-lymphocyte-associated protein 4 ( CTLA -4) that has been shown to negatively regulate antigen receptor 
signaling upon engagement of its ligands (PD- L1 and/or PD- L2).[21, 22] 
The structure of murine PD-1 has been resolved [Zhang et al., 2004].  PD -1 and its family 
members are type I transmembrane glycoproteins containing an Ig- variable –type (IgV- type) 
domain responsible for ligand binding and a cytoplasmic tail responsible for the binding of signaling molecules.  The cytoplasmic tail of PD -1 contains 2 tyrosine- based signaling motifs, an 
immunoreceptor tyrosine-based inhibition motif, and an immunoreceptor tyrosine- based switch 
motif.   Following T- cell stimulation, PD -1 recruits the tyrosine phosphatases, SHP-1 and SHP-2, 
to the immunoreceptor tyrosine- based switch m otif within its cytoplasmic tail, leading to the 
dephosphorylation of effector molecules such as CD3 zeta (CD3ζ), protein kinase C -theta 
(PKCθ), and zeta -chain -associated protein kinase (ZAP70), which are involved in the CD3 T- cell 
signali ng cascade.[ 22-25 ]  The  mechanism by [CONTACT_13209]-[ADDRESS_587030] from, that of CTLA -4, because both molecules regulate an overlappi[INVESTIGATOR_13015].[ 26, 27]  As a consequence, the PD-1/PD- L1 pathway is an attractive target 
for therapeutic intervention in NSCLC.  
1.3.[ADDRESS_587031] clinical activity in NSCLC.  
IRB Protocol Number:  2019C0145  
IRB Approval date:  06/10/2022  
Version:  05/06/2022  
 
PROTOCOL NUMBER: OSU-[ZIP_CODE]        
   
 Page 3 Ramucirumab is approved in combination with docetaxel for NSCLC. The phase III REVEL trial evaluated second line docetaxel + ramucirumab/placebo, including EGFR mutant patients (n=33, 5%). The addition of ramucirumab improved median OS (10.5 months vs 9.1 months , p=0.023) as 
well as RR (23% vs 14%, p<0.0001) for the overall NSCLC population. [ 28, 
29]  
Pembrolizumab, an anti- PD-[ADDRESS_587032] line and second line therapy. [ 30-32] In non-mutated NSCLC, 
pe
mbrolizumab – as a single agent or with chemotherapy - is associated with response rates ≥ 
20%.[ 30] The use of checkpoint inhibitors in patients with EGFR mutations has been more 
nuanced. A recent phase II study of pembrolizumab in TKI-naïve EGFR mutant lung cancer was 
stopped early (only 11 patients were enrolled) due to futility.  A retrospective cohort study 
confirmed these findings; the cohort included 110 EGFR mutant patients with response rate of 
12% to ICI.[ 5] These results suggest low efficacy for single agent checkpoint inhibitors but do 
not exclude potential synergy of combination therapi[INVESTIGATOR_014]. [20, 21]  
A recent phase I study evaluated ramucirumab (R) and pembrolizumab (P) in multiple tumor types, 
i
ncluding EGFR wild type  NSCLC (n=22). The primary objective of the study was to assess safety 
and tolerability of R+P (R 10 mg/kg and P 200 mg on day 1 of 21 day cycle). The study concluded that there were no new concerning safety signals at full doses of ea ch mAb; it also demonstrated 
encouraging antitumor activity in previously treated EGFR wild type  NSCLC (RR – 18- 45% when 
stratified by [CONTACT_422013]1).  
1.4 Clinical Safety  
Pembrolizumab and ramucirumab are both approved by [CONTACT_2165] 
(FDA) for commercial use in NSCLC but have not been approved in combination.  Measures 
will be taken to ensure the safety of the patients participating in this trial including the use of stringent inclusion and exclusion criteria and close monitoring.  Toxicity grading will be performed in accordance with NCI CTCAE, Version 5.0.  If more than one different type of toxicity occurs concurrently, the most severe grade will determine the modification.  
If toxicities are encountered, adjustments will be made to the study t reatment as detailed in the 
sections below.  All AEs and SAEs will be recorded during the trial and for up to [ADDRESS_587033].  
1.5 Phase II Single Arm  Trial of Ramucirumab and Pembrolizumab  in EGFR mutant 
Non-Small Cell Lung Cancer  
1.5.1 Rationale for the Study  
Non-small cell lung cancer (NSCLC) is among the most common and most lethal cancer in the 
[LOCATION_002]. Of these patients, approximately 15% have tumors with sensitizing EGFR driver mutations. Sensitizing mutations, in particular exon [ADDRESS_587034] line response rates of > 70% with tyrosine kinase inhibitors (TKI). [3] Although these drugs are highly 
effective, responses are not durable and most patients will develop progressive disease. After first or second generation TKI, osimertinib is available for patients with T790M mutation. Current 
therapi[INVESTIGATOR_459674]. Immunotherapy appears to 
IRB Protocol Number:  2019C0145  
IRB Approval date:  06/10/2022  
Version:  05/06/2022  
 
PROTOCOL NUMBER: OSU-[ADDRESS_587035] an evolving role in this population. Single agent immunotherapy (PDL1 inhibitors) have been associated with low response rates in these patients. Given the synergistic activity of pembrolizumab (P) and ramuciramab (R) in phase 1 trials, we propose a single arm phase II trial of R+P in EGFR mutant NSCLC patients who have progressed on EGFR TKI. 
EGFR Mutations in NSCLC  
EGFR driver mutations are associated with sensitivity to EGFR inhibition  with tyrosine kinase 
inhibitors. The first and second generation EGFR inhibitors – gefitinib, erlotinib, and afatinib – 
demonstrated dramatic improvements in response rates and progression free survival (PFS) in 
EGFR mutant patients when compared to first  line chemotherapy.[ 2, 33-35] Despi[INVESTIGATOR_459675], patients ultimately progress. Up to 60% of patients receiving erlotinib , afatinib, or 
gefitinib develop T790M resistance mutation and can be salvaged with osimertinib, a third generation EGFR inhibitor.[ 36] The FLAURA trial then compared first line osimertinib to 
erlotinib and demonstrated a significant improvement in PF S, moving osimertinib into first line as 
the preferred agent. [4]
 
When osimertinib is used in the first line setting, the mechanisms of resistance are yet to be  fully 
characterized and no cases of T790M mutation were reported in the phase 1 study in nine patients with previously untreated EGFR  mutation –positive advanced NSCLC who received 
osimertinib. [37] Some reported mechanisms in patients with T790M -positive NSCLC after 
EGFR -TKI treatment include acquired  EGFR  mutations (C797S), MET and  HER2  amplification, 
and small -cell transformation. [38-41]
 Second line options after osimertinib currently include 
cytotoxic chemotherapy, immunotherapy, or chemoimmunotherapy. 
Immunotherapy in NSCLC  
Immunotherapy (IO), specifically PD/PDL1 inhibition, has emerged as an important option for 
management of NSCLC. The immune system p lays a role in  prevention/treatment of 
cancer  through surveillance and cytotoxic killing of tumor cells. Tumor growth may occur due to 
immune dysregulation; immunotherapy by [CONTACT_459689], stimulate immu ne response  and eliminate tumor cells by [CONTACT_459690].  Pembrolizumab is a selective humanized IgG4 kappa monoclonal 
antibody that inhibits the pPD -[ADDRESS_587036] line therapy, it is utilized either in patients with tumor PD -L1 expression ≥ 50 % as a single agent or in 
combination with chemotherapy (regardless of PD -L1 expression).[ 30, 31]
 For second line (or 
later), pembrolizumab is approved for patients with tumor PD -L1 ≥1.[ 32] Across these trials, 
pembrolizumab – as a single agent or with chemotherapy - is safe and effective in NSCLC with 
response rates ≥ 20%. Specifically in patients with high PD -L1 expression (≥ 50 %), response rate 
to single agent pembrolizumab is 44.8% (compared to 27.8% with chemotherapy doublet).[ 30] 
The use of checkpoint inhibitors in patients with EGFR mutations has been more nuanced. Many 
of the early trials either excluded EGFR  mutant patients or included limited numbers of EGFR 
patients. BIRCH (phase II trial of single agent atezolizumab) included 45 EGFR mutant patients 
IRB Protocol Number:  2019C0145  
IRB Approval date:  06/10/2022  
Version:  05/06/2022  
 
PROTOCOL NUMBER: OSU-[ZIP_CODE]        
   
 Page 5 who progressed or did not tolerate TKI therapy. Response rates were similar for “first line” EGFR 
mutant (compared to wild -type) but lower for patients in second/third line.[ 42] Two other single 
agent  atezolizumab trials also included EGFR mutant patients (POPLAR and OAK). [43, 44] OAK  
included 85 EGFR mutant patients; a  subgroup analys is of EGFR -mutant patients favored 
chemotherapy over atezolizumab (HR, 1.24; 95% CI, 0.21- 2.18), suggesting a lack of benefit for these patients. [44] T
he phase 3 IMpower150 trial (carboplatin, paclitaxel, bevacizumab and 
atezolizumab) also included EGFR mutant patients. As in the BIRCH trial, “first line” EGFR mutant patients were required to  have received at least 1 TKI prior to enrollment. A total of 80 
EGFR mutant patients were included – 35 received atezolizumab, 45 received chemotherapy 
alone. There was a benefit with the addition of atezolizumab in PFS (9.7 months vs 6.1 months). 
[16] N otably, EGFR mutants have been excluded from most trials with pembrolizumab. A recent 
phase II study of pembrolizumab in TKI -naïve EGFR mutant lung cancer was stopped early (only 
11 patients were enrolled) due to futility.  These results suggest low efficacy for single agent 
checkpoint inhibitors but do not exclude potential synergy of combination therapi[INVESTIGATOR_014].  
Anti- Angiogenic Agents in NSCLC  
Anti-a ngiogenic agents, particularly VEGF inhibitors, have demonstrated activity in EGFR mutant NSCLC. Ramucirumab is a human monoclonal antibody that targets the VEGF receptor -2, an 
important key receptor implicated in angiogenesis and for tumor growth.  It inhibits angiogenesis by [CONTACT_459688] -2 inhibiting binding of VEGF 
receptor ligands VEGF -A, VEGF -C, and VEGF -D. The phase III REVEL trial evaluated second 
line docetaxel + ramucirumab or placebo. It has been approved as second -line for patients with 
advanced or metastatic non -small cell lung cancer (NSCLC) in combination with docetaxel. EGFR 
mutant patients were permitted if they had received both TKI and platinum -based chemotherapy, 
although there were only 33 EGFR mutant patients on the trial (≤ 3% of overall study population). The addition of ramucirumab improved median OS (10.5 months vs 9.1 months , p=0.023) as well 
as RR (23% vs 14%, p<0.0001). Primary toxicities related to ramucirumab included hypertension and bleeding. Results were similar across histologic subgroups.[ 28, 29] Ramucirumab is currently 
approved as second- line therapy for patients with advanced/metastatic  NSCLC in combination 
with docetaxel.  
Based on these findings of activity of anti-VEGF therapy in EGFR mutant NSCLC and  synergy between P+R, we propose a phase II single arm trial to evaluate the efficacy of R+P in EGFR mutant NSCLC patients.  
1.5.2 Rationale for Starting Dose and Dosing Schedule  
A phase I study evaluated ramucirumab (R) plus pembrolizumab (P) in patients with multiple tumor types, including a NSCLC cohort (n=27). One dosing regimen was evaluated in a phase 1a 
for NSCLC: R 10 mg/kg and P 200 mg on day 1 of 21 day cycle. The primary objective of the study was to assess safety and tolerability of R+P. The study concluded that there were no new concerning safety signals; it also demonstrated encouraging antitumor activity in previously treated NSCLC - RR 30%, median PFS 9.7 months.[ 45]  
Based on this phase 1 data, our study will use the same dose and doing schedule. 
IRB Protocol Number:  2019C0145  
IRB Approval date:  06/10/2022  
Version:  05/06/2022  
 
PROTOCOL NUMBER: OSU-[ADDRESS_587037] scan will be used for objective tumor assessment at baseline and then at 6 week/[ADDRESS_587038] criteria will also  be assessed (Table 1). For 
patients with progressive disease by [CONTACT_393], treatment may be continued for up to 2 additional cycles if the primary physician feels there is clinical benefit (Figure 1). If progression is confirmed on second scan, treatment will be discontinued.  
1.5.[ADDRESS_587039] 1.1 will be used as the primary measure for assessment of tumor response, date of 
disease progression, and as a basis for all protocol guidelines related to disease status (eg, discontinuation of study treatment).  Although RECIST 1.[ADDRESS_587040] publication. [46]  iRECIST wi ll be used by [CONTACT_459691], and make treatment decisions.   
Table 1 : Imaging and Treatment after First Radiologic Evidence of Progressive Disease 
 Clinically Stable  Clinically Unstable  
Imaging Treatment  Imaging Treatment  
First radiologic 
evidence of PD by [CONTACT_393] 1.1  Repeat imaging at 4 to 8 weeks to confirm PD.  May continue study treatment at the Investigator’s discretion while awaiting confirmatory tumor imaging by [CONTACT_246111].  Repeat imaging at 4 to 8 weeks to confirm PD per Investigator’s discretion only. Discontinue treatment  
IRB Protocol Number:  2019C0145  
IRB Approval date:  06/10/2022  
Version:  05/06/2022  
 
PROTOCOL NUMBER: OSU-[ZIP_CODE]        
   
 Page 7  Clinically Stable  Clinically Unstable  
Imaging Treatment  Imaging Treatment  
Repeat tumor 
imaging 
confirm s PD 
(iCPD) by [CONTACT_459692]. Discontinue 
treatment 
(exception is possible upon consultation with Sponsor). No additional 
imaging 
required. Not applicable 
Repeat tumor imaging shows iUPD by [CONTACT_459693] 4 to 8 weeks to confirm PD.  May occur at next regularly scheduled imaging visit.  Continue study treatment at the Investigator’s discretion. Repeat imaging at 4 to 8 weeks to confirm PD per Investigator’s discretio n 
only. Discontinue treatment  
Repeat tumor imaging shows iSD, iPR, or iCR by [CONTACT_459694].  Continue regularly scheduled imaging assessments.  Continue study treatment at the Investigator’s discretion. Continue regularly scheduled imaging assessments.  May restart study treatment if condition has improved and/or clinically stable per Investigator’s discretion.  Next tumor image should occur according to the regular imaging schedule.  
iCPD = iRECIST confirmed progressive dis ease; iCR = iRECIST complete response; 
iRECIST = modified Response Evaluation Criteria in Solid Tumors 1.1 for immune- based 
therapeutics; iSD = iRECIST stable disease; iUPD = iRECIST unconfirmed progressive disease; PD = progressive disease; RECIST 1.1 = R esponse Evaluation Criteria in Solid 
Tumors 1.1..  
 
  
 
IRB Protocol Number:  2019C0145  
IRB Approval date:  06/10/2022  
Version:  05/06/2022  
 
PROTOCOL NUMBER: OSU-[ZIP_CODE]        
   
 Page 8 Figure 1: Imaging and Treatment for Clinically Stable Participants after First Radiologic Evidence of PD Assessed by [CONTACT_737] 
 
2. OBJECTIVES AND ENDPOINTS  
2.1 Primary Objective  
To evaluate response rate of the combination of ramucirumab and pembrolizumab in EGFR mutant NSCLC.  
Primary Endpoint : 
 Overall response rate (ORR): Response rate will be evaluated with 
CT scans every [ADDRESS_587041] (iRECIST) will also be assessed  (see Appendices  1 and 2 for details) .  
2.2 S
econdary Objectives  
To evaluate safety, tolerability, and survival for patients receiving pembrolizumab and ramucirumab.  
Secondary Endpoints : 
 Safety, tolerability, clinical benefit rate (responses + stable 
disease), progression-free and overall survival.  

IRB Protocol Number:  2019C0145  
IRB Approval date:  06/10/2022  
Version:  05/06/2022  
 
PROTOCOL NUMBER: OSU-[ZIP_CODE]        
   
 Page 9 2.3 Exploratory objectives  
To characterize predictive immunologic biomarkers of response in tissue and peripheral blood of patients receiving ramucirumab and pembrolizumab combination therapy  
Exploratory Endpoints : 1
 ) Baseline tumor immunoprofile by [CONTACT_4658], including tumor 
infiltrating lymphocytes and T cell receptor (TCR) immunosequencing (immunoSEQ) and relationship to clinical outcomes, including response rate. 2)  C irculating immune cell 
profiles in response to treatment and in relation to clinical response using  CyTOF  profile 
on peripheral blood samples. 3) C irculating VEGF at baseline, after treatment and at 
progression to evaluate correlation with clinical response 
 
3.
 INVESTIGATIONAL PLAN 
3.[ADDRESS_587042] one EGFR TKI.   Each treatment cycle will be 21 days. Patients will receive ramucirumab 10 mg/kg and pembrolizumab 200 mg IV on day 1. Dosing of pembrolizumab and ramucirumab is based on prior phase 1 tes ting of the combination.  
 
All trial treatments will be administered on an outpatient basis.  
 
The treatment to be used in this trial is outlined below in Table 2 
Table 2:  Trial Treatment  
Drug  Dose/  
Potency  Dose 
Freque
ncy Route of 
Administration  Regimen/  
Treatment Period  Use 
Ramucirumab  10 mg/kg  Q3W  IV infusion  Day 1 of each 3 
week cycle  Experimental  
Pembrolizumab  200 mg  Q3W  IV infusion  Day 1 of each 3 
week cycle  Experimental  
 
 
Tumor tissue will be collected at baseline. Peripheral blood samples will be collected at baseline, cycle 3 day 1, and at progression (or study discontinuation).  
During the treatment period, patients will undergo physical examination monthly and CT scans 
at baseline and then approximately every 6 weeks (2 cycles) thereafter. The disease status will be assessed per RECIST v.1.[ADDRESS_587043] ( immune RECIST ) criteria  (Appendices  1 and 2). 
IRB Protocol Number:  2019C0145  
IRB Approval date:  06/10/2022  
Version:  05/06/2022  
 
PROTOCOL NUMBER: OSU-[ZIP_CODE]        
   
 Page 10 Patients will be treated  for up to 35 cycles or until confirmed progression of disease or the 
development of unacceptable toxicities. All patients will then undergo a final visit (end of treatment visit).  
3.1.1 Definition of Treatment Cycle and Duration  
Ramucirumab and pembrolizumab will be administered on day 1 of each cycle. One cycle is defined as 21 days. 
3.1.2 Timing of Dose Administration 
Trial treatment should be administered on Day 1 of each cycle after all procedures/assessments 
have been completed as detailed on t he Trial Flow Chart (Section 6.3).  Trial treatment may be 
administered up to [ADDRESS_587044] followed by [CONTACT_79911].  
Ramucirumab 10 mg/kg will be administered as an IV infusion every 3 weeks.  Administer 
initial infusion over 60 minutes; if tolerated, may administer subsequent infusions over 30 
minutes  starting with cycle 2 . Given  the variability of infusion pumps from site to site, a window 
of -5 minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 min). 
Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.  Sites 
s
hould make every effort to target infusion timing to be as close to 30 minutes as possible.  
However, given the variability of infusion pumps from site to site, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 m in). 
The Pharmacy Manual contains specific instructions for the preparation of the pembrolizumab infusion fluid and administration of infusion solution. 
3.1.[ADDRESS_587045] scan, unacceptable toxicities occur in individual subjects, or consent is withdrawn.  
3.1.4 End of Treatment Visit  
Patients that discontinue from treatment will undergo an end of treatment visit, regardless of the 
reason of discontinuation, 30 (+/- 14) days after the last dose of study medication. 
This study to be conducted at The Ohio State University Wexner Medical Center. If the protocol meets criteria to proceed with enrol lment after initial futility analysis, we will consider expansio n 
to include additional sites.     
3.2 Study Duration  
Patients will receive pembrolizumab and ramucirumab day 1 during each 21- day cycle.  Patient 
may continue on study drugs until disease progression or for up to 35 cycles .  Objective 
assessment of disease progression will be performed every six weeks.  
IRB Protocol Number:  2019C0145  
IRB Approval date:  06/10/2022  
Version:  05/06/2022  
 
PROTOCOL NUMBER: OSU-[ADDRESS_587046] patient in (FPI). With an expected accrual rate of 1 patients every 2 months, and a total number of 34 patients planned (if 
trial p roceeds to second stage), the anticipated enrollment period is [ADDRESS_587047] 6 weeks.  
 
IRB Protocol Number:  2019C0145  
IRB Approval date:  06/10/2022  
Version:  05/06/2022  
 
PROTOCOL NUMBER: OSU-[ZIP_CODE]        
   
 Page 12 3.3 Study Schema  
Figure 2: Study Schema  
 
 
 
 
 
  
 
  
 
  
  Treatment Phase  Screening Phase  
Post Treatment 
Follow- Up Eligibility Assessment –  
• NSCLC EGFR mutant (sensitizing mutations - exon 19 or exon 21) 
• Prior TKI therap y (first or second line, including 2nd line osimertinib 
for T790M positive patients) 
• ECOG performance status 0 -1 
Treatment Plan  
Ramucirumab 10 mg/kg + Pembrolizumab 200 mg IV  
Day 1 of 21 day cycle 
Response assessment: CT scan every 2 cycles  
Progressive Disease (PD)  
May continue beyond progression if 
clinical benefit  
Confirm PD with repeat CT scan at 
least [ADDRESS_587048] scan  Stable Disease (SD)  
 Partial Response (PR)  
 Complete Response  (CR)  
Treatment will be continued for up 
to 35 cycles  
Patient follow -up by [CONTACT_17084]/or chart review (if patient unavailable) for 
survival  
IRB Protocol Number:  2019C0145  
IRB Approval date:  06/10/2022  
Version:  05/06/2022  
 
PROTOCOL NUMBER: OSU-[ZIP_CODE]        
   
 Page 13 Figure 3 : Correlative Study Schedule  
 
4. PATIENT SELECTION  
This Investigator Initiated T rial will be conducted in compliance with the protocol, GCP and all 
applicable regulations.   
4.1 Study Population and Sample Size  
This trial will be open to non- small cell lung cancer (NSCLC) patients with sensitizing EGFR 
mutations who have received first or second line therapy with tyrosine kinase inhibitor (TKI). 
These are most commonly lung adenocarcinoma but there are no restrictions for histology.  
Planned enrollment is up to 34 patients. There will be a 2 stage design with a planned interim 
analysis for futility planned after the initial 13  patients  (stage 1)  have been followed for at least [ADDRESS_587049] meet all of the following inclusion criteria to be eligible to enroll in this study.  
1. Male/female participants who are at least 18 years of age on the day of signing informed consent in accordance with federal, local, and institutional guidelines 
2. Histologically confirmed recurrent or metastatic non -small cell carcinoma of the lung with 
sensitizing EGFR mutations. Exon 20 resistance mutations will not be permitted but uncommon sensitizing mutations are allowed. 
3. Prior Systemic Anticancer Therapy: N eo/adjuvant therapy or prior therapy for locally 
advanced disease will be permitted . Patients with prior exposure to PD/PD -L1 inhibitors 
will be excluded. No limit on  prior EGFR TKIs (erlotinib, gefitinib, afatinib, dacomitinib  
or osimertinib). Patients who develop progressive disease after erlotinib, gefitinib, afatinib, or dacomitinib must either receive osimerintib (T790M positive) or be T790M negative. Prior chemotherapy for metastatic disease is permitted. A [ADDRESS_587050] criteria.  

IRB Protocol Number:  2019C0145  
IRB Approval date:  06/10/2022  
Version:  05/06/2022  
 
PROTOCOL NUMBER: OSU-[ADDRESS_587051] adequate organ function as defined in the following table (Table  3).  Specimens must 
be collected within 1 0 days prior to the start of study treatment 
Table 3:  Adequate Organ Function Laboratory Values 
 
System  Laboratory Value 
Hematological   
Absolute neutrophil count (ANC) ≥1500/µL 
Platelets  ≥100 000/µL  
Hemoglobin ≥9.0 g/dL or ≥5.6 mmol/La 
Renal   
Creatinine OR  
Measured or calculatedb creatinine 
clearance  
(GFR can also be used in place of creatinine or CrCl)  ≤1.5 × ULN OR  
≥40 mL/min for participant with creatinine levels >1.5  × institutional ULN  
Urine protein ≤1+ on dipstick or routine urinalysis (UA; if urine dipstick or routine analysis is ≥2+, a 24-hour urine collection for protein must 
demonstrate <1000 mg of protein in 24 hours to allow participation in this protocol). 
Hepatic   
Total bilirubin  ≤1.5 ×ULN OR direct bilirubin ≤ULN for 
participants with total bilirubin levels >1.5 ×  ULN  
AST (SGOT) and ALT (SGPT)  ≤2.5 ×  ULN (≤5  × ULN for participants 
with liver metastases)  
Coagulation  
International normalized ratio (INR) OR prothrombin time (PT) 
Activated partial thromboplastin time 
(aPTT)  ≤1.5 ×  ULN unless participant is receiving 
anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants
c 
IRB Protocol Number:  2019C0145  
IRB Approval date:  06/10/2022  
Version:  05/06/2022  
 
PROTOCOL NUMBER: OSU-[ADDRESS_587052]  be either postmenopausal, surgically sterile, or using effective contraception 
(hormonal or barrier methods).  
• A male participant must agree to use a contraception as detailed in Appendix [ADDRESS_587053] dose of study treatment and refrain from donating sperm during this period. 
• A female participant is eligible to participate if she is not pregnant (see Appendix 
5), not breastfeeding, and at least one of the following conditions appli es:  
a) Not a woman of childbearing potential (WOCBP) as defined in Appendix 5  OR  b.) A WOCBP who agrees to follow the contraceptive guidance in Appendix [ADDRESS_587054] 2 years (i.e.  with 
use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pi[INVESTIGATOR_13002], etc.) is not considered a form of systemic treatment.  ALT (SGPT)=alanine aminotransferase (serum glutamic pyruvic transaminase); AST  (SGOT)=aspartate aminotransferase (serum glutamic oxaloacetic transaminase); 
GFR=glomerular filtration rate; ULN=upper limit of normal.  
a Criteria must be met without erythropoietin dependency and without packed red blood 
cell (pRBC) transfusion within last 2 weeks.  
b Creatinine clearance (CrCl) should be calculated per institutional standard.  
c Patients on full-dose anticoagulation must be on a stable dose (minimum duration 14 
days) of oral anticoagulant or low molecular weight heparin (LMWH). If receiving warfarin, the patient must have an INR ≤3.0. For heparin and LMWH there should be  no active bleeding (that is, no bleeding within [ADDRESS_587055] dose of protocol therapy) or pathological condition present that carries a high risk of bleeding (for example, tumor involving major vessels or known varices). 
Note: This table includes eligibility -defining laboratory value requirements for treatment; 
laboratory value requirements should be adapted according to local regulations and 
guidelines for the administration of specific chemotherapi[INVESTIGATOR_014]. 
IRB Protocol Number:  2019C0145  
IRB Approval date:  06/10/2022  
Version:  05/06/2022  
 
PROTOCOL NUMBER: OSU-[ZIP_CODE]        
   
 Page 16 2. Known active chronic infections – HIV/AIDS, known active Hepatitis B or C . Known history 
of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active Hepatitis C virus (defined as HCV RNA [ qualitative]  is detected) infection. Note: no testing 
for Hepatitis B and Hepatitis C is required unless mandated by [CONTACT_14306].  
3. Cirrhosis (Child -Pugh B or worse) or cirrhosis with history of hepatic encephalopathy or 
clinically meaningful ascites resulting from cirrhosis. Clinically meaningful ascites is defined as ascites from cirrhosis requiring diuretics or paracentesis. 
4. Prior exposure to ramucirumab. 
5. Has received prior therapy with an anti -PD-1, anti- PD-L1, or anti- PD-L2 agent or with an 
agent directed to ano ther stimulatory or co -inhibitory T- cell receptor (eg,  CTLA -4, OX-40, 
CD137). 
6. Any Grade [ADDRESS_587056] dose of protocol therapy. 
7. History of deep vein thrombosis (DVT), pulmonary embolism (PE), or any other significant thromboembolism (venous port or catheter thrombosis or superficial venous thrombosis are not considered “significant”) during the [ADDRESS_587057] dose of protocol therapy. 
8. Patients receiving dipyridamole, clopi[INVESTIGATOR_7745], or similar agents.  Once -daily aspi[INVESTIGATOR_34308] 
(maximum dose 325 mg/day) is permitted.  
9. Uncontrolled CNS metastases. Patients with treated brain metastases are eligible if they were 
clinically stable with regard to  neurologic function, off steroids after cranial irradiation 
(whole brain radiation therapy, focal radiation therapy, and stereotactic radiosurgery) ending at least [ADDRESS_587058] no evidence of 
Grade ≥[ADDRESS_587059] scan (performed within [ADDRESS_587060] dose of study treatment). Note:  Patients who received s ystemic 
therapy that adequately and appropriately treated CNS metastases, including tyrosine kinase inhibitors, are eligible provided that CNS disease control is confirmed by [CONTACT_459686] [ADDRESS_587061] dose of study treatment. 
10. Hem
op tysis (defined as bright red blood or ≥  1/2 teaspoon) within [ADDRESS_587062] 
dose of protocol therapy or with radiographic evidence of intratumor cavitation or has 
radiologically documented evidence of major blood vessel invasion or encasement by c ancer.  
11. U ncontrolled or poorly-controlled hypertension (>160 mmHg systolic or > 100 mmHg 
diastolic for >4 weeks) despi[INVESTIGATOR_328784].  
12. Any arterial thromboembolic events, including but not limited to myocardial infarction, transient ischemic attack, cerebrovascular accident, or unstable angina, within [ADDRESS_587063] dose of protocol therapy.  Patient has elective or planned major surgery to be performed during the course of the clinical trial.  
14. Serious or non-healing wound, ulcer, or bone fracture within 28 days of study treatment.  
15. Prior history of GI perforation/fistula (within [ADDRESS_587064] dose of protocol therapy) or risk factors for perforation.  
16. Small cell or mixed (small cell/non -small cell) lung cancer  
17. Pregnancy  or breastfeeding.  
IRB Protocol Number:  2019C0145  
IRB Approval date:  06/10/2022  
Version:  05/06/2022  
 
PROTOCOL NUMBER: OSU-[ADDRESS_587065] dose of study drug.  Examples of live vaccines include, but are not limited to,  the following:  measles, mumps, rubella, 
varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette–Guérin (BCG), and typhoid vaccine.  Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg,  FluMist®) are live attenuated 
vaccines and are not allowed.  
19. History of (non-infectious) pneumonitis that required steroids or has current pneumonitis. 
20. History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject’s participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opi[INVESTIGATOR_80021].   
21. Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.  
22. Severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipi [INVESTIGATOR_840]. 
23. Active infection requiring systemic therapy. 
24. Known history of active TB   (Bacillus Tuberculosis).    
4.4 Lifestyle Restrictions  
[IP_ADDRESS] Meals and Dietary Restrictions  
Participants should maintain a normal diet unless modifications are required to manage an AE such as diarrhea, nausea or vomiting. 
[IP_ADDRESS] Contraception  
Ramuricumab and/or Pembrolizumab may have adverse effects on a fetus in utero.  Refer to 
Appendix [ADDRESS_587066] azoospermia (whether due to having had a vasectomy or due to an underlying medical condition).   
Pregnancy  
If a participant in advertently becomes pregnant while on treatment with pembrolizumab, the 
participant will be immediately discontinued from study treatment.  The site will contact [CONTACT_459695]’s status until the pregnancy has been completed or terminated.  The outcome of the pregnancy will be reported to [COMPANY_006] within 2 working days if the outcome is a serious adverse experience (eg, death, abortion, congenital anomaly, or other disabling or life- threatening complication to the  mother or newborn).  The 
study Investigator will make every effort to obtain permission to follow the outcome of the pregnancy and report the condition of the fetus or newborn to [COMPANY_006].  If a male participant impregnates his female partner, the study pers onnel at the site must be informed immediately and 
the pregnancy must be reported to [COMPANY_006] and followed as described in Section 7.2.2. 
IRB Protocol Number:  2019C0145  
IRB Approval date:  06/10/2022  
Version:  05/06/2022  
 
PROTOCOL NUMBER: OSU-[ADDRESS_587067]-feeding are not eligible for enrollment. 
4.5 Patient Removal from Study Treatment  
Patients may be removed from the study treatment  at any time for the following reasons: 
• Disease progression  
• Noncompliance with study procedures 
• Need of treatment with medications not allowed by [CONTACT_4690] 
• The participant  or  participant’s legally acceptable representative requests to discontinue 
study treatment 
• Intercurrent illness that interferes with study assessments  
• Incidence or severity of AEs in this study indicates a potential health hazard to the patient 
(Investigator discretion) 
• Pregnancy  
• At the discretion of the treating investigator after discussion with principal investigator  
• Termination of the study by [CONTACT_459696]  
• Ramucirumab specific criteria for end of study treatment: 
o Grade 3 and 4 arterial thromboembolic events, or any PE/DVT occurring or worsening during anticoagulant therapy, require permanent discontinuation of ramucirumab therapy. Any venous or arterial event leading to discontinuation of ramucirumab therapy will be considered serious and should be reported via the serious adverse event (SAE) mechanism.  
o Any patient who experiences signs of hepatic encephalopathy or other serious signs of liver impairment such as hepatorenal syndrome must be permanently discontinued from ramucirumab therapy. 
o The patient will have ramucirumab permanently discontinued if the protein level is >3 g/[ADDRESS_587068] occurrence of >2 g/24 hours, or if the protein level does not return to <2 g/[ADDRESS_587069] not 
receive further treatment with ramucirumab.  
o Ramucirumab should be permanently discontinued in the event of a gastrointestinal p erforation or fistula formation. 
o If Reversible Posterior Leukoencephalopathy (RPLS) is diagnosed, ramucirumab must be permanently discontinued. All cases of RPLS must be reported via the SAE mechanism.  
IRB Protocol Number:  2019C0145  
IRB Approval date:  06/10/2022  
Version:  05/06/2022  
 
PROTOCOL NUMBER: OSU-[ZIP_CODE]        
   
 Page 19 o Completion of 35 treatments (approximately 2 years) wi th ramucirumab.  
• Pembrolizumab specific criteria for end of study treatment (detailed in Table 5):  
o Recurrent grade 3 toxicity  
o Recurrent Grade 2 pneumonitis 
o Grade 4 toxicity, except for endocrinopathies (as detailed in Table 5) 
o Completion of 35 treatments (approximately 2 years) with pembrolizumab 
• Patients who complete [ADDRESS_587070] Name & Potency  Dosage Form  
Ramucirumab  10 mg/1 ml  Solution for Injection  
 Premedication: Diphenhydramine 50 mg intravenous (IV) 30 minutes prior to infusion. 
For patients with infusion reaction (grade 1 or 2), premedication should also include 
dexamethasone 10 mg IV and acetaminophen 650 mg oral (PO). 
5.[ADDRESS_587071] be recorded by [CONTACT_131895].  
 
5.3 Ramucirumab Labelling  
Supplies will be labeled in accordance with regulatory requirements.  
5.4 Ramuc irumab Dosing Information 
The planned dose of ramucirumab is 10 mg/kg IV every 3 weeks (Q3W). This is the FDA 
approved dose for non- small cell lung cancer. This is also the dose that was  utilized in phase 1 
combination testing of ramucirumab and pembrolizumab.[ 45] 
IRB Protocol Number:  2019C0145  
IRB Approval date:  06/10/2022  
Version:  05/06/2022  
 
PROTOCOL NUMBER: OSU-[ADDRESS_587072] Name & Potency  Dosage Form  
Pembrolizumab 100 mg/ 4mL  Solution for Injection  
 
5.[ADDRESS_587073] be recorded by [CONTACT_80098]. 
5.7 Pembrolizumab Labelling  
Supplies will be labeled in accordance with regulatory requirements.  
5.8 Pembrolizumab  Dosing Information 
The planned dose of pembrolizumab for this study is 200 mg every 3 weeks (Q3W).  Based on the totality of data generated in the Keytruda development program, 200 mg Q3W is the appropriate dose of pembrolizumab for adults across all indications and regardless of tumor type.    As outlined below, this dose is justified by: 
• Clinical data from 8 randomized studies demonstrating flat dose- and exposure -
efficacy relationships from 2 mg/kg Q3W to 10 mg/kg every 2 weeks (Q2W),  
• Clinical data showing meaningful improvement in benefit-risk including overall survival at 200 mg Q3W across multiple indications, and 
• Pharmacology data showing full target saturation in both systemic circulation (inferred from pharmacokinetic [PK] data) and tumor (inferred from physiologically-based PK [PBPK] analysis) at 200 mg Q3W 
 Among the 8 randomized dose-comparison studies, a total of 2262 participants were enrolled with melanoma and non-small cell lung cancer (NSCLC), covering different disease settings (treatment naïve, previously treated, PD- L1 enriched, and all -comers) and different treatment 
settings (monotherapy and in combination with chemotherapy).  Five studies compared 2 mg/kg 
Q3W versus 10 mg/kg Q2W (KN001 Cohort B2, KN001 Cohort D, KN002, KN010, and KN021), and 3 studies compared 10 mg/kg Q3W versus 10 mg/kg Q2W (KN001 Cohort B3, KN001 Cohort F2 and KN006).  All of these studies demonstrated flat dose- and exposure-response relationships across the doses studied representing an approximate 5- to 7.5 fold difference in exposure.  The 2 mg/kg (or 200 mg fixed-dose) Q3W provided similar respons es to 
the highest doses studied.  Subsequently, flat dose-exposure-response relationships were also 
IRB Protocol Number:  2019C0145  
IRB Approval date:  06/10/2022  
Version:  05/06/2022  
 
PROTOCOL NUMBER: OSU-[ADDRESS_587074], PK data in KN001 evaluating target-mediated drug disposition (TMDD) conclusively demonstrated saturation of PD-[ADDRESS_587075] tumor PD-1 saturation over a wide range of tumor 
penetration and PD-1 expression.  This evaluation concluded that pembrolizumab at 200 mg Q3W achieves full PD -1 saturation in both blood and tumor. 
Finally, population PK analysis of pembrolizumab, which characterized the influence of body weight and other participant covariates on exposure, has shown that the fixed-dosing provides similar control of PK variability as weight based dosing, with considerable overlap in the distribution of exposures from the 200 mg Q3W fixed dose and 2 mg/kg Q3W dose.  Supported by [CONTACT_131877], and given that fixed-dose has advantages of reduced dosing complexity and reduced potential of dosing errors, the 200 mg Q3W fixed- dose was selected for 
evaluation  across all pembrolizumab protocols.  
5.9 Handling – Ramucirumab and Pembrolizumab  
Qualified personnel, familiar with procedures that minimize undue exposure to themselves and 
the environment, should undertake the preparation, handling, and safe disposal of th e 
chemotherapeutic agent in a self -contained and protective environment.  
5.[ADDRESS_587076] study drug by [CONTACT_459697].  The Investigator (or designee) will verify and acknowledge receipt of all study drug shipments by [CONTACT_37396].  
Study drug accountability records will be maintained at the site pharmacy and will be available 
for review by [CONTACT_358719].  
All medication must be stored in a secure area under the proper storage requirements with access 
restricted to the site staff pharmacist or designee(s).  
The Investigational medicinal product should not be used for any purpose outside the scope of this protocol, nor can Investigational medicinal product be transferred or licensed to any party not participating in the clinical study. Data for Investigational medicinal product are confidential and proprietary and shall be maintained as such by [CONTACT_32366]. 
The Investigator, or a responsible party designated by [CONTACT_737], must maintain a careful 
record of the inventory and disposition of unused material.  
All clinical drug supplies must be kept in an appropriate, limited access, secure place until used 
or returned to Lilly or [COMPANY_006] or designee for destruction. After study drug is reconciled, drug 
IRB Protocol Number:  2019C0145  
IRB Approval date:  06/10/2022  
Version:  05/06/2022  
 
PROTOCOL NUMBER: OSU-[ADDRESS_587077] of the inventory and disposition of al l agents.  
 
6. STUDY PROCEDURES   
Data will be collected via the completion of a Case Report Form (CRF) for each eligible patient. 
The investigator should confirm eligibility of the patient according to the inclusion and exclusion criteria of the study. All patients have to provide written  Informed Consent before any study 
specific assessment is performed. A study specific assessment is defined as a procedure that is not part of the routine assessments performed for diagnostic purposes or standard care. Screening assessments should occur within [ADDRESS_587078] dose of study treatment as soon as possible after registration, but not later than 7 days after registration. 
6.1 Study Assessments  
6.1.1 Efficacy Assessments  
Primary Endpoint : 
 The response rate of R+P  will be evaluated using RECIST 1.[ADDRESS_587079] 
criteria  (Appendi ces 1 and 2 ) will be determined by [CONTACT_459698]. Tumor progression will be determined by [CONTACT_459699].  The baseline disease assessment must be recorded and measured within 28 days prior to treatment start. During the treatment period, disease assessments will be performed every 6 weeks, i.e. once every two cycles, and as clinically indicated.  
 
Secondary Endpoints : S
 afety and tolerability will be assessed with adverse event (AE) 
assessments at each study visit. CTCAE v5.0 will be used for adverse event grading. Attributions 
of causality will be assessed by [CONTACT_140882]. Clinical benefit rate (stable disease + responses) will be assessed using the same criteria as response rate and on the same schedule. Survival will be measured from the date of study registration to the date of event (i.e., de
ath or progressive disease) or the date of last follow-up if no event has occurred at their last 
evaluation. 
6.1.[ADDRESS_587080], and coagulation. 
 
IRB Protocol Number:  2019C0145  
IRB Approval date:  06/10/2022  
Version:  05/06/2022  
 
PROTOCOL NUMBER: OSU-[ZIP_CODE]        
   
 Page 23 6.1.3 Summary Table for Specimen Collection  
Biomarker Name  [CONTACT_459716]: 
Baseline 
TCR immunoSEQ /multiplex 
IHC 
  Formalin -Fixed -
Paraffin -Embedded 
(FFPE) tumor tissue (archival  or fresh 
biopsy), 5-10 slides per patient   Ohio State University – Carbone lab 
Cycle 1, Day 1 
CyTOF panel  Pre-treatment  Blood (1x heparin tubes, 10 ml) Ohio State University  Carbone 
Lab/Li lab (PI[INVESTIGATOR_459676])  
TCR immunoSEQ  Pre-treatment  Blood (1 x heparin 
tubes, 10 mla) Ohio State University Carbone lab/Li lab (PI[INVESTIGATOR_459676])  
VEGF Elisa  Pre-treatment  Blood (1x heparin tubes, 10 ml
a) Ohio State University – Carbone lab/Li lab (PI[INVESTIGATOR_459676])  
Cycle 3, Day 1  
CyTOF panel Pre-treatment  Blood ((1x heparin tubes, 10 ml*) Ohio State University – Carbone lab/Li lab (PI[INVESTIGATOR_459676])  
TCR immunoSEQ  Pre-treatment  Blood (1x heparin tubes, 10 ml
a) Ohio State University – Carbone lab/Li lab (PI[INVESTIGATOR_459676])  
VEGF Elisa  Pre-treatment  Blood (1x heparin tubes, 10 ml
a) Ohio State University – Carbone lab/Li lab (PI[INVESTIGATOR_459676])  
End of Treatment or Progressive Disease  
IRB Protocol Number:  2019C0145  
IRB Approval date:  06/10/2022  
Version:  05/06/2022  
 
PROTOCOL NUMBER: OSU-[ZIP_CODE]        
   
 Page 24 CyTOF panel  Blood ((1x heparin tubes, 10 ml) Ohio State University – Carbone lab/Li lab (PI[INVESTIGATOR_459676])  
TCR immunoSEQ   Blood (1x heparin tubes, 10 ml
a) Ohio State University – Carbone lab/Li lab (PI[INVESTIGATOR_459676])  
VEGF Elisa   Blood (1x heparin tubes, 10 ml
a) Ohio State University – Carbone lab/Li lab (PI[INVESTIGATOR_459676])  
TCR immunoSEQ  
Molecular testing/multiplex IHC  
 Optional at progression Formalin -Fixed 
Paraffin -Embedded 
(FFPE) tumor tissue (archival or fresh biopsy), 5-10 slides per patient  Ohio State University – Carbone lab/Li lab (PI[INVESTIGATOR_459676])  
a – Same tube will be used for TCR and VEGF 
Sample Collection for translational /correla tive analyses 
 Correlative study assessments will be included:  Tumor biopsies:  A
 rchival or fresh biopsy will be utilized. For archival tissue, we will request a 
minimum of 5 slides (FFPE).  Tissue will be tested for expression of biomarkers of response 
including TCR immunoSEQ  and cancer specific markers to the tumor by [CONTACT_9064]. 
Tumor tissue will be kept with the intention to perform tests as new techniques, research tools, 
an
d biomarkers become available.  
Blood (2 tubes x 10 ML): BD Vacutainer (heparin tubes) will be used for blood collection. 
Peripheral blood will be analyzed for circulating immune cell profiles in relation to clinical response using CyTOF profile at baseline and prior to cycle 3. Peripheral blood analysis will also include TCR immunosequencing (immunoSEQ) and VEGF (ELISA) at baseline, during treatment and at progression. 
Peripheral blood for CyTOF  p
 rofile will be collected at 3 time points (baseline and cycle 2, day 1  
at progression/end of treat ment ) for the initial 13 patients (stage 1).  If a patient discontinues 
treatment after cycle 2, EOT samples will be collected at that time.  Peripheral blood 
mononuclear cells (PBMC) and plasma for remaining correlative studies (TCR immunoSEQ and VEGF) wil l be preserved from collected blood samples at 3 time points: baseline (pre- treatment 
day 1), prior to cycle 3, and at study discontinuation or disease progression. Correlative studies will be collected as scheduled even if one of the two drugs is held/discontinued.  
Samples will be stored for batching of correlative studies (TCR immunoSEQ and VEGF). 
IRB Protocol Number:  2019C0145  
IRB Approval date:  06/10/2022  
Version:  05/06/2022  
 
PROTOCOL NUMBER: OSU-[ADDRESS_587081] continuous review of data and patient safety at 
their regular disease group meetings (at least monthly) and the discussion will be documented in 
the minutes. The PI [INVESTIGATOR_459677]/benefit ratio of the trial changes. 
Frequency and severity of adverse events will be reviewed by [CONTACT_978] [INVESTIGATOR_459678]/device from other sources; including published literature, scientific 
meetings and discussions with the investigators , to determine if the trial should be terminated 
before completion. Serious adverse events and responses will also be reviewed by [CONTACT_459700] (DSMC). The PI [INVESTIGATOR_37354] a progress report 
(biannually for Phase II and quarterly for Phase I) that will be reviewed by [CONTACT_459701]. All reportable Serious Adverse Events (SAE) will also be reported to the IRB of 
record as per the policies of the IRB.  
Throughout the treatment period until one month after the last dose of study medication, patients 
w
ill be assessed for all adverse events. National Cancer Institute Common Terminology Criteria 
for Adverse Events (CTCAE v 5.0) will be used for grading. If necessary, the patient may be withdrawn from the study treatment.  
6.3 Schedule of Study Events   
The Schedule o f Study Events is shown in Table 4
Table 4.     
 
 PROTOCOL NUMBER: OSU-[ZIP_CODE]          
 Page 26 Table 4.  Schedule of Study Events  
Assessments Screening/  
Baseline  Cycle 1*  Cycle 1  Cycle 2  Cycle 
2 Cycle 
3 + End of 
Treatment  
Visit window [days] Within 
28 days Within 
10 days  Within  
7 days Day 1  Day 8  Day 1  Day 8  Day 1  30 days  
 +/- 3 
days  +/- 3 
days ± [ADDRESS_587082] (if applicable)3  X      X  
Vital signs and weight5  X  X X X X X X 
Physical examination and 
ECOG   X X X X X X X 
Urine analysis6  X  X X X X X X 
Hematology7  X  X    X X 
Coagulation studies8  X      X7  
Complete Serum chemistry9  X  X X X X X X 
TSH 10  X      X9  
Peripheral blood correlative 
studies11    X    X11 X 
Tumor biopsy11 X        X 
Assessment of disease 
status12 X       X X 
Ramucirumab dosing     X  X  X  
Pembrolizumab dosing     X  X  X  
Adverse event assessment     X  X  X X 
Concomitant Medication   X  X  X  X X 
Study Assessment Footnotes  
 
 PROTOCOL NUMBER: OSU-[ZIP_CODE]          
 Page 27 * Each treatment cycle is [ADDRESS_587083] on day 1 of cycle 1 to confirm pregnancy status prior to treatment. Repeat urine pregnancy testing for women 
of childbearing potential every 9 weeks or if pregnancy is suspected . Positive urine pregnancy testing will require confirmation with 
serum pregnancy testing. 
5 Vital signs: Weight, blood pressure, pulse and temperature 
6 Urine analysis will include appearance, color, glucose, hemoglobin, ketones, pH, and protein. Microscopy will only be performed if 
clinically indicated . Urine dipstick protein > 1+ will require 24 hour urine collection for urine protein assessment. 24 urine collection 
will include measurement of both protein and creatinine. 
7 Hematology: Complete blood count including differential is required.  WBC differential may be automated or manual as per 
institutional standards.  
8 Coagulation studies will include P T/INR and PTT. These studies will be repeated every 3rd cycle or as needed (for patients on active 
anti-coagulation). 
9 Complete Serum Chemistry  includes: sodium, potassium, chloride, bicarbonate, BUN, creatinine, glucose, calcium, phosphate, 
magnesium, ALT, AST, alkaline phosphatase, total bilirubin, total protein, albumin. 
10 TSH will be performed at baseline - free  T3/free T4 to be checked if TSH is out of the normal range.  
11  Correlative studies  (peripheral blood) will be dra wn pre -treatment on cycle 1 day  1; cycle 3 day 1 , and at final study visit. Tumor 
biopsy sample (archival) will be collected at study enrollment. Optional tumor biopsy at progression if clinically indicated. 
[ADDRESS_587084] scan every  6 weeks (+/ - 7 days) for the first 6 months and then every 12 weeks and as 
clinically indicated. Baseline imaging within 28 days of study initiation. 
 
 PROTOCOL NUMBER: OSU-[ZIP_CODE]          
 Page 28  
6.3.1 Screening Assessments  
All patients will be screened and screening procedures performed within 10 days (unless 
otherwise noted) prior to the start of induction treatment. These include the following:  
 
Signed written informed consent  Obtained prior to any study specific assessments 
Inclusion/Exclusion Criteria  
(Day -28 to 1) 
 • Age 
• Tumor diagnosis 
• Prior therapi[INVESTIGATOR_014]  
• Comorbid conditions  
Demographics and Medical 
History  • Age, gender, ethnic background 
• Previous and concurrent relevant diseases  
• Current symptoms and/ or residual toxicities from 
prior therapi[INVESTIGATOR_014]  
• Details on prior cancer therapy, including start and stop dates, disease progression during or after therapy, as well as discontinuation due to toxicities  
Concomitant medication Concomitant medication currently used will be documented. 
Pregnancy test (if applicable)  A serum pregnancy test will be performed in women of child-bearing potential: pre-menopausal women and women who are post-menopausal for < 2 years.  
Physical examination and vital 
signs  
(Day -7 to 1) • Body height and weight  
• Vital signs: Blood pressure, pulse, temperature  
• Physical examination  
• ECOG performance status (App endix 3)  
Urine analysis  Appearance, color, urine bilirubin, glucose, hemoglobin, ketones, pH, protein, specific gravity, 
urobilinogen.  
Hematology (CB C) 
 Hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, white blood cell (WBC) count, WBC differential, red blood cell count, lymphocytes, monocytes, neutrophils, band neutrophils, eosinophils, basophils, platelets.  WBC differential may be automated or manual as per institutional standards.  
 
 PROTOCOL NUMBER: OSU-[ADDRESS_587085], alkaline phosphat ase, total bilirubin, total 
protein, albumin 
Assessment of disease status (Day -
28 to 1) The disease status will be measured by [CONTACT_3610]  
(Chest/Abdomen/Pelvis). MRI brain will be done as clinically indicated.  
Tumor biopsy - archival  Archival tumor biopsy material (paraffin embedded 
and formalin fixed) will be collected, if available.  If 
standard of care biopsy is performed, fresh tumor cells will be collected f or study.  
 
 
6.3.2 Treatment Phase 
During the treatment phase the following assessments are to be performed  (see Schedule of 
Study Events in Table 4 for timing of assessments in each cycle).  
Physical examination and vital 
signs • Body weight  
• Blood pressure, pulse, temperature  
• Physical examination (symptom directed)  
 
Urine analysis  
(every  other cycle) Urine bilirubin, glucose, hemoglobin, ketones, pH, 
protein 
Hematology  Hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, white blood cell (WBC) count, WBC differential, red blood cell count, lymphocytes, monocytes, neutrophils, band neutrophils, eosinophils, basophils, platelets.  WBC differential may be automated or manual as per 
institutional standards.  
Complete clinical chemistry  
 Sodium, potassium, chloride, bicarbonate, BUN, creatinine, glucose, calcium, phosphate, magnesium, ALT, AST, alkaline phosphatase, total bilirubin, total protein, albumin  
TSH  If TSH is abnormal, free T3 and free T4 will also  be 
measured. Repeat TSH every 3rd cycle  
 
Pregnancy test (if applicable)  A urine pregnancy test will be performed on cycle [ADDRESS_587086] cycle or  if pregnancy is 
suspected in women of child -bearing potential: pre -
 
 PROTOCOL NUMBER: OSU-[ADDRESS_587087] -
menopausal for < 2 years.  
Adverse events and concomitant 
medication  Assessed on an ongoing basis 
 
6.3.3 Tumor Imaging and Assessment of Disease  
Tumor imaging is strongly preferred to be acquired by [CONTACT_20420] (CT).  For the 
abdomen and pelvis, contrast- enhanced magnetic resonance imaging (MRI) may be used when 
CT with iodinated contrast is contraindicated, or when local practice m andates it.  MRI is the 
strongly preferred modality for imaging the brain.  The same imaging technique regarding modality, ideally the same scanner, and the use of contrast should be used in a participant throughout the study to optimize the reproducibility of the assessment of existing and new tumor burden and improve the accuracy of the assessment of response or progression based on imaging. 
Expedited confirmation of measurable disease based on RECIST 1.1 at Screening should be used 
to determine participant eligibility.  Confirmation that the participant’s imaging shows at least [ADDRESS_587088] on -study imaging assessment should be performed at 6 weeks (42  days ±7 days]) from 
the date of allocation.   Subsequent tumor imaging should be performed every 6 weeks (42 days 
±7 days) or more frequently if clinically indicated.  After [ADDRESS_587089] imaging performed every 12 weeks ( 84 days ±7 days).  Imaging timing 
should follow calendar days and should not be adjusted for delays in cycle starts.  Imaging should continue to be performed until disease progression is identified by [CONTACT_737].  
Objective response should be confirmed by a repeat imaging assessment.  Tumor imaging to 
confirm PR or CR should be performed at least [ADDRESS_587090] indication of a response is observed.  Participants will then return to regular scheduled imaging every 6 weeks, starting with 
the next scheduled imaging time point.  Participants who receive additional imaging for confirmation do not need to undergo the next scheduled tumor imaging if it is less than 4 weeks later; tumor imaging may resume at the sub sequent scheduled imaging time point.   
 
 PROTOCOL NUMBER: OSU-[ADDRESS_587091] (Appendix 2), disease progression should be confirmed by [CONTACT_779] [ADDRESS_587092] radiologic evidence of PD in clinically stable participants  as defined by [CONTACT_76798] 2 
(Note - if patient  is receivi ng clinical benefit,  oligoprogressive CNS  disease that can be controlled  
with local therapy such as stereotactic radiation , may continue on treatment beyond progression 
with PI [INVESTIGATOR_41473]. Ramucirumab should be held for [ADDRESS_587093] radiation for CNS oligoprogression as long as ramucirumab is held for 4- 6 weeks afterwards. 
Ramucirumab can be restarted after this time if the patient is asymptomatic, clinically stable and this is considered appropriate by [CONTACT_093] .).  Par ticipants who have unconfirmed disease 
progression may continue on treatment at the discretion of the Investigator until progression is confirmed by [CONTACT_459702] [IP_ADDRESS].  Participants who receive confi rmatory imaging do not need to undergo the next scheduled tumor 
imaging if it is less than 4 weeks later; tumor imaging may resume at the subsequent scheduled imaging time point, if clinically stable.  Participants who have confirmed disease progression by [CONTACT_19393], as assessed by [CONTACT_779], will discontinue study treatment.   
  
6.3.[ADDRESS_587094] and end of treatment (EOT) visit 
completed 30 days (± 14 days) after the last application of study drug. 
At the EOT visit, the patients will undergo the following assessments: 
Physical examination and vital 
signs • Body weight  
• Blood pressure, pulse, temperature  
• Physical examination  
Urine analysis  Urine bilirubin, glucose, hemoglobin, ketones, pH, 
protein 
Hematology  Hemoglobin, hematocrit, mean corpuscular volume, 
mean corpuscular hemoglobin, mean corpuscular 
hemoglobin concentration, white blood cell (WBC) count, WBC differential, red blood cell count, lymphocytes, monocytes, neutrophils, band neutrophils, eosinophils, basophils, platelets. WBC differential may be automated or manual as per institutional standards.  
Complete serum chemistry  Sodium, potassium, chloride, bicarbonate, BUN, 
creatinine, glucose, calcium, phosphate, magnesium, ALT, AST, alkaline phosphatase, total bilirubin, total protein, albumin  
Assessment of disease status CT scan (if not performed within the last 28 days) 
Adverse events and concomitant 
medication  Assessed on an ongoing basis  
 
 
 PROTOCOL NUMBER: OSU-[ZIP_CODE]          
 Page 32 In participants who discontinue study treatment, tumor imaging should be performed at the time of treatment discontinuation (±4 week window).  If previous imaging was obtained within [ADDRESS_587095], this is the final required tumor imaging. 
In participants who discontinue study treatment without documented disease progression, every 
effort should be made to continue monitoring their disease status by [CONTACT_388107] (every 12 weeks in Year 1 or every 24 weeks after Year 1) to monitor disease status until the start o f a new anticancer treatment, disease 
progression, pregnancy, death, withdrawal of consent, or the end of the study, whichever occurs first. 
6.3.[ADDRESS_587096]-study survival data may alternatively  be obtained during 
patient visits to site or source documents from other medical visits.  
6.4 End of Study  
The primary statistical analysis will be performed when 80% of the events for the secondary 
analysis of PFS have occurred.  This will ensure appropriate follow-up time for the primary endpoint of ORR and for the secondary endpoints of PFS and OS. 
6.5 Planned T reatment of the Patients after End of Treatment Phase  
After completion of the study at routine follow- up (EOT), patients will generally be treated at the 
discretion of the investigator according to medical routine. 6.6 Removal of Patients from Treatment  
Subjects will be free to discontinue treatment or withdraw from the study at any time, for any 
reason, or they may be withdrawn/ removed if necessary in order to protect their health (see reasons for withdrawal below). It is understood by [CONTACT_459703] e xcessive rate of 
withdrawals can render the study uninterpretable; therefore, unnecessary withdrawal of subjects should be avoided.  
If there is a medical reason for withdrawal of treatment, the patient will remain under the 
supervision of the investigator until the AEs have been resolved or declined to baseline values. 
If a patient has failed to attend scheduled assessments in the study, the investigator must 
determine the reasons and circumstances as completely and accurately as possible.  
In case of prem ature discontinuation of the study treatment, the investigations scheduled for the 
EOT should be performed, if possible. The CRF section entitled “End of Treatment” must be 
completed in all cases. Should a patient decide to withdraw, every effort will be m ade to 
complete and report the observations as thoroughly as possible. The investigator should contact 
 
 [CONTACT_459704]: OSU-[ZIP_CODE]          
 Page 33 the patient to determine as completely as possible the reason for the withdrawal. A complete final evaluation at the time of the patient’s withdrawal sho uld be made, with an explanation of 
why the patient is withdrawing from the study. If the reason for removal of a patient from the study is an adverse event or an abnormal laboratory test result, the principal specific event or test will be recorded on the case report form.  
6.7 Study Discontinuation  
Early trial termination will be the result of the criteria specified below:  
1. Quality or quantity of data recording is inaccurate or incomplete 
2. Poor adherence to protocol and regulatory requirements 
3. Incidence or sever ity of adverse drug reaction in this or other studies indicates a potential health 
hazard to participants  
4. Plans to modify or discontinue the development of the study drug 
In the event of decision by [CONTACT_459705] ([COMPANY_006] or Lilly) to no longer supply study drug, ample 
notification will be provided so that appropriate adjustments to participant treatment can be made.  
7. TOXICITIES, RISKS AND AE -RELATED DOSE MODIFICATIONS  
7.1 Ramucirumab Toxicity Overview  
Ramucirumab is currently approved by [CONTACT_2165] (FDA)  fo r 
commercial use in combination with docetaxel in non-small cell lung cancer. The combination of 
pembrolizumab with ramucirumab is investigational. The entire safety profile of the combination 
therapy is not known at this time. Measures will be taken to ensure the safety of the patients 
participating in this trial, including the use of stringent inclusion and exclusion criteria and close 
monitoring. Toxicity grading will be perfor med in accordance with NCI CTCAE version 5.0. If 
more than one different type of toxicity occurs concurrently, the most severe grade will 
determine the modification.  
7.1.1
 Risks Associated with Ramucirumab  
Potential risks and toxicities of ramucirumab are detailed in the manufacturer’s package insert (https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125477s002lbl.pdf).  
7.1.2 Dose Modification for Ramucirumab  
Infusion- R
elated Reactions (IRR):  
• Reduce infusion rate by 50% of grade 1 or 2 IRR. 
• Grade 1 or 2 IRR should receive pre -medication with dexametha sone and acetaminophen 
prior to subsequent infusions. 
• Grade 3 or 4 IRR: Discontinue ramucirumab. 
Hypertension 
 
 PROTOCOL NUMBER: OSU-[ZIP_CODE]          
 Page 34 • Hold ramucirumab for severe hypertension (Uncontrolled or poorly-controlled hypertension (>160 mmHg systolic or > 100 mmHg diastolic) until controlled with medical management.  
• Discontinue ramucirumab for severe hypertension (>160 mmHg systolic or > 100 mmHg diastolic for >4 weeks ) that cannot be controlled with antihypertensive therapy. 
Proteinuria: 
• If a patient has proteinuria with 24 hour urine protein ≥  2 g, ramucirumab should be held. 
When level returns to less than 2 g/24 hr, may resume at a reduced dose of 8 mg/kg every 
3 weeks. If level 2 g/24 hr or greater recurs, interrupt therapy again, and when level 
returns to less than 2 g/24 hr, resume at a reduced dose of 6 mg/kg every 3 weeks.  
• For nephrotic syndrome or urine protein > 3 g/24 hr, ramucirumab should be permanently 
discontinued.  
Wound Healing: 
• Hold ramucirumab prior to surgery and until the wound is fully healed.  
Indications for permanent discontinuation of R am ucirumab  
• IRR: Patients with grade [ADDRESS_587097] not receive further treatment 
with ramucirumab.  
• Hypertension: Patients with grade [ADDRESS_587098] not re ceive further treatment with 
Ramucirumab.  
• Proteinuria: The patient will have ramucirumab permanently discontinued if the protein level is >3 g/[ADDRESS_587099] occurrence of >2 g/24 hours, or if the protein level does not return to <2 g/24 hours within 2 weeks. 
• Thromboembolism: Grade 3 and 4 arterial thromboembolic events, or any PE/DVT occurring or worsening during anticoagulant therapy, require permanent discontinuation of ramucirumab therapy. Any venous or arterial event leading to discontinuation of ramucirumab therapy will be considered serious and should be reported via the serious adverse event (SAE) mechanism.  
• Hepatic disease: Any patient who experiences signs of hepatic encephalopathy or other serious signs of liver impairment such as hepatorenal syndrome must be permanently discontinued from ramucirumab therapy. 
• Ramucirumab should be permanently discontinued in the event of a gastrointestinal 
perforation or fistula formation. 
• If Reversible Posterior Leukoencephalopathy (RPLS) is diagnosed, ramucirumab must be 
permanently discontinued. All cases of RPLS must be reported via the SAE mechanism. 
  
For all other toxicities, ramucirumab may be held for up to [ADDRESS_587100] be postmenopausal, surgically sterile, or using effective contraception (hormonal or barrier methods).   
 
 PROTOCOL NUMBER: OSU-[ADDRESS_587101] at screening ( < [ADDRESS_587102] dose) and negative urine pregnancy 
test on day [ADDRESS_587103]- menopausal. Total (true) abstinence (when this is in line with the 
preferred and usual lifestyle of the patient), is  an acceptable method of contraception.  Periodic 
abstinence (e.g., calendar, ovulation, symptothermal, post - ovulation methods) and withdrawal 
are not acceptable methods of contraception.  For both male and female patients, effective methods of contraception must be used throughout the study and for three months following the last dose.  
7.2 P
embrolizumab  Toxicity Overview 
Pembrolizumab is currently approved by [CONTACT_459706] a tion (FDA) for 
commercial use as a single agent and in combination with cytotoxic chemotherapy for non -small 
cell lung cancer . The combination of pembrolizumab with ramucirumab is investigational. T he 
entire safety profile of the combination therapy is not known at this time. Measures will be taken 
to ensure the safety of the patients participating in this trial, including the use of stringent 
inclusion and exclusion criteria and close monitoring. Toxicity grading will be performed in accordance with NCI C TCAE version 5.0. If more than one different type of toxicity occurs 
concurrently, the most severe grade will determine the modification. 
If toxicities are encountered, adjustments will be made to the study treatment as detailed in the 
s
ections below. All AEs and SAEs will be recorded during the trial and for up to [ADDRESS_587104].  
 
7.2.1 Risks Associated with Pembrolizumab  
Potential risks and toxicities associated with Pembrolizumab are detailed in the Investigator’s 
Brochure.  
7.2.2 Dose Modifications for Pembrolizumab  
Pembrolizumab may be held up to 12 weeks for immune- related toxicity. If a patient has a n 
immune -related toxicity that does not resolve within 12 weeks, pembrolizumab will be 
discontinued  
AEs associated with pembrolizumab exposure may represent an immunologic etiology. These 
immune -related AEs (irAEs) may occur shortly after the first dose or several months after t he 
last dose of pembrolizumab treatment and may affect more than on body system simultaneously. Therefore, early recognition and initiation of treatment is critical to reduce complications.  Based on existing clinical study data, most irAEs were reversible and could be managed with interruptions of pembrolizumab, administration of corticosteroids and/or other supportive care. 
 
 PROTOCOL NUMBER: OSU-[ZIP_CODE]          
 Page 36 For suspected irAEs, ensure adequate evaluation to confirm etiology or exclude other causes. Additional procedures or tests such as bronchoscopy, endoscopy, skin biopsy may be included as part of the evaluation. Based on the severity of irAEs, withhold or permanently discontinue pembrolizumab and administer corticosteroids. Dose modification and toxicity management guidelines for irAEs associated with pembrolizumab are provided below in Table 5.   
 
7.3 Study Drug Discontinuation If either ramucirumab or pembrolizumab is held or discontinued for toxicity, the remaining 
drug may be continued as maintenance therapy for up to 35 cycles or disease progression or unacceptable toxicity.  
 
PROTOCOL NUMBER: OSU -[ZIP_CODE]  
  
CONFIDENTIAL  
 Table 5. Dose modifications and toxicity management guidelines for immune- related AEs associated with pembrolizumab  
General instructions:  
1. Corticosteroid taper should be initiated upon AE improving to Grade [ADDRESS_587105] dose or  
corticosteroids cannot be reduced to ≤[ADDRESS_587106] followed by [CONTACT_44874]. Other immunosuppressive treatment 
should be initiated if irAEs cannot be controlled by [CONTACT_13216].  
 
Immune -
related AEs  Toxicity grade 
or conditions 
(CTCAEv 5.0) Action taken to 
pembrolizumab  irAE management with 
corticosteroid and/or 
other therapi[INVESTIGATOR_44790] -up  
Pneumonitis  Grade 2  Withhold  • Administer 
corticosteroids (initial 
dose of 1- 2 mg/kg 
prednisone or equivalent) 
followed by [CONTACT_13217] 
 • Monitor participants for signs and symptoms of pneumonitis  
• Evaluate participants with suspected pneumonitis with 
radiographic imaging and initiate corticosteroid treatment  
• Add prophylactic antibiotics for opportunistic infections  Grade 3 or 4, 
or recurrent Grade 2  Permanently 
discontinue 
Diarrhea / 
Colitis  Grade 2 or 3  Withhold  • Administer 
corticosteroids (initial 
dose of 1- 2 mg/kg 
prednisone or equivalent) followed by [CONTACT_13217] 
 • Monitor participants for signs and symptoms of enterocolitis 
(ie, diarrhea, abdominal pain, blood or mucus in stool with or without fever) and of bowel perforation (ie, peritoneal signs and ileus). 
• Participants with ≥ Grade 2 diarrhea suspecting colitis should 
consider GI consultation and performing endoscopy to rule 
out colitis.  
• Participants with diarrhea/colitis should be advised to drink liberal quantities of clear fluids.  If sufficient oral fluid intake is not feasible, fluid and electrolytes should be substituted via 
IV infusion.  Recurrent 
Grade 3  
or 
Grade 4  Permanently 
discontinue 
PROTOCOL NUMBER: OSU -[ADDRESS_587107] / ALT 
elevation or 
Increased bilirubin  Grade 2  Withhold  • Administer 
corticosteroids (initial 
dose of 0.5- 1 mg/kg 
prednisone or equivalent) 
followed by [CONTACT_13217]  • Monitor with liver function tests (consider weekly or more 
frequently until liver enzyme value returned to baseline or is stable  
Grade 3 or 4  Permanently 
discontinue • Administer 
corticosteroids (initial 
dose of 1- 2 mg/kg 
prednisone or equivalent) 
followed by [CONTACT_44878] 1 diabetes 
mellitus (T1DM) or Hyperglycemia 
 Newly onset 
T1DM or  
Grade 3 or 4 hyperglycemia associated with 
evidence of β -
cell failure  Withhold  • Initiate insulin 
replacement therapy for 
participants with T1DM  
• Administer anti-
hyperglycemic in 
participants with 
hyperglycemia  
 • Monitor participants for hyperglycemia or other signs and 
symptoms of diabetes. 
Hypophysitis  Grade 2  Withhold  • Administer 
corticosteroids and 
initiate hormonal 
replacements as clinically 
indicated.   
 • Monitor for signs and symptoms of hypophysitis (including 
hypopi[INVESTIGATOR_44791])  
Grade 3 or 4  Withhold or 
permanently discontinue
1  
Hyperthyroidis
m  Grade 2  Continue  • Treat with non -selective 
beta- blockers (eg, 
propranolol) or 
thionamides as 
appropriate  • Monitor for signs and symptoms of thyroid disorders.  
 
Grade 3 or 4  Withhold or  
permanently 
discontinue1 
PROTOCOL NUMBER: OSU -[ZIP_CODE]  
  
CONFIDENTIAL  
 Hypothyroidis
m Grade 2 -4 Continue  • Initiate thyroid 
replacement hormones 
(eg, levothyroxine or 
liothyroinine) per 
standard of care  • Monitor for signs and symptoms of thyroid disorders.  
 
Nephritis and 
Renal 
dysfunction Grade 2  Withhold  • Administer 
corticosteroids (prednisone 1- 2 mg/kg or 
equivalent) followed by 
[CONTACT_13217].  • Monitor changes of renal function  
 Grade 3 or 4  Permanently 
discontinue 
Myocarditis  Grade 1 or 2  Withhold  • Based on severity of AE 
administer corticosteroids  • Ensure adequate evaluation to confirm etiology and/or 
exclude other causes  
 Grade 3 or 4  Permanently 
discontinue  
All other 
immune -related 
AEs Intolerable/ 
persistent 
Grade 2  Withhold  • Based on type and 
severity of AE administer corticosteroids  • Ensure adequate evaluation to confirm etiology and/or 
exclude other causes  
 
Grade 3  Withhold or 
discontinue based on the type of event.  Events that require discontinuation include and not limited to:  Gullain -Barre 
Syndrome, 
encephalitis  
Grade 4 or 
recurrent 
Grade 3  Permanently 
discontinue 
PROTOCOL NUMBER: OSU -[ZIP_CODE]  
  
CONFIDENTIAL  
 1. Withhold or permanently discontinue pembrolizumab is at the discretion of the investigator or treating physician.   
NOTE:  
For participants with Grade 3 or 4 immune-related endocrinopathy where withhold of pembrolizumab is required, pembrolizumab may be 
resumed when AE resolves to ≤ Grade 2 and is controlled with hormonal replacement therapy or achieved metabolic control (in cas e of T1DM).   
  Table 6. Pembrolizumab Infusion Reaction Dose modification and Treatment Guidelines  
PROTOCOL NUMBER: OSU -[ZIP_CODE]  
  
CONFIDENTIAL  
 NCI CTCAE 
Grade  Treatment  Premedication at 
Subsequent Dosing  
Grade 1  
Mild reaction; 
infusion interruption not indicated; intervention not 
indicated  Increase monitoring of vital signs as 
medically indicated until the participant is deemed medically stable in the opi[INVESTIGATOR_871]. None  
Grade 2  
Requires therapy or infusion interruption but responds promptly to symptomatic treatment (e.g., antihistamines, NSAIDs, narcotics, 
IV fluids); 
prophylactic medications indicated for ≤24 hrs Stop Infusion.  
Additional appropriate medical therapy may include but is not limited to:  
IV fluids  
Antihistamines  
NSAIDs  
Acetaminophen  
Narcotics  
Increase monitoring of vital signs as 
medically indicated until the participant 
is deemed medically stable in the opi[INVESTIGATOR_871]. If symptoms resolve within 1 hour of stoppi[INVESTIGATOR_13056], the infusion may be restarted at 50% of the original infusion rate (e.g. from 100 mL/hr to 50 mL/hr).  Otherwise dos ing will be held 
until symptoms resolve and the participant should be premedicated for the next scheduled dose. 
Participants who develop Grade 2 toxicity despi[INVESTIGATOR_459679] 1.5h (± 30 minutes) prior to infusion of _____ with: 
Diphenhydramine 50 mg po (or equivalent dose of antihistamine).  
Acetaminophen 500-1000 mg po (or 
equivalent dose of 
analgesic).  
Grades 3 or 4  
Grade 3:  
Prolonged (i.e., not rapi[INVESTIGATOR_14137]/or brief interruption of infusion); recurrence of symptoms following 
initial improvement; Stop Infusion.  
Additional appropriate medical therapy may include but is not limited to:  
Epi[INVESTIGATOR_238]** IV fluids  
Antihistamines  
NSAIDs  
Acetaminophen  
Narcotics  
Oxygen 
Pressors  No subsequent dosing  
PROTOCOL NUMBER: OSU -[ZIP_CODE]  
  
CONFIDENTIAL  
 7.3.1 Dose modification and toxicity management of infusion- reactions related 
to pembrolizumab  
Pembrolizumab may cause severe or life threatening infusion -reactions including severe 
hypersensitivity or anaphylaxis. Signs and symptoms usually develop during or shortly after 
drug infusion and generally resolve completely within 24 hours of completion of infusion. Dose modification and toxicity management guidelines on pembrolizumab associated infusion reaction are provided in Table 6.    
 hospi[INVESTIGATOR_113749] (e.g., renal impairment, pulmonary infiltrates)  
Grade 4:  
Life-threatening; 
pressor or ventilatory support 
indicated  Corticosteroids  
Increa se monitoring of vital signs as 
medically indicated until the participant is deemed medically stable in the opi[INVESTIGATOR_871]. Hospi[INVESTIGATOR_13021].  
**In cases of anaphylaxis, epi[INVESTIGATOR_13079]. Participant is permanently discontinued from further study drug treatment.  
Appropriate resuscitation equipment should be available at the bedside and a physician 
readily available during the period of drug administration. 
For further information, please refer to the Common Terminology Criteria for Adverse 
Events v5.0 (CTCAE) at http://ctep.cancer.gov  
PROTOCOL NUMBER: OSU -[ZIP_CODE]  
  
CONFIDENTIAL  
 7.3.2 Other allowed dose interruption for pembrolizumab  
Pembrolizumab may be interrupted for situations other than treatment- related AEs such as 
medical / surgical events or logistical reasons not related to study therapy. Participants should be 
placed back on study therapy within 3 weeks of the scheduled interruption, unless otherwise discussed with the Sponsor. The reason for interruption should be documented in the patient's study record. 
8. SUPPORTIVE CARE GUIDELINES   
8.1 Concomitant Medications  
Medications or vaccinations specifically prohibited in the exclusion criteria are not allowed 
during the ongoing trial.  If there is a clinical indication for one of these or other medications or vaccinations specifically prohibited during the trial, discontinuation from trial therapy or vaccination may be required.  The final decision on any supportive therapy or vaccination rests with the investigator and/or the participants's primary physician.  
8.[ADDRESS_587108] care.  Medications to treat concomitant diseases like diabetes, hypertension, etc., are allowed. 
8.3 Glucocorticoid therapy  
Glucocorticoids (≤  20 mg oral prednisone or equivalent) per day are permitted at baseline and 
during the study for non- malignant c onditions (i.e., asthma, irritable bowel disease, etc.,) as 
needed, but patients should preferably have been on a stable dose for at least two weeks before 
study entry. 
8.4 Prohibited Medication  
Participants are prohibited from receiving the following therapi[INVESTIGATOR_80025] (including retreatment for post- complete response relapse) of this trial: 
• Antineoplastic systemic chemotherapy or biological therapy  
• Immunotherapy not specified in this protocol 
• Chemotherapy not specified in this protocol 
• Investigational agents other than pembrolizumab 
• Chronic antiplatelet therapy, including aspi[INVESTIGATOR_248], nonsteroidal anti -inflammatory drugs 
(NSAIDs, including ibuprofen, naproxen, and others), dipyridamole or clopi[INVESTIGATOR_7745], or similar ag ents is not permitted. Once -daily aspi[INVESTIGATOR_34308] (maximum dose 325 mg/day) is 
permitted.  
• Radiation therapy  
o Note:  Radiation therapy to the brain may be allowed after consultation with the PI [INVESTIGATOR_459680]. See section 6.3.5. .  Ramucirumab therapy 
should be  temporarily discontinued for 2 weeks prior to starting radiation.  However, 
PROTOCOL NUMBER: OSU -[ADDRESS_587109] radiation for CNS 
oligoprogression as long as ramucirumab is held for 4- 6 weeks afterwards. 
Ramucirumab can be restarted after this time if the patient is asymptomatic, 
clinically stable and this is considered appropriate by [CONTACT_093].  
• Live vaccines within [ADDRESS_587110] dose of study treatment and while participating in the study.  Examples of live vaccines include, but are not limited to, the 
followi ng: measles, mumps, rubella, varicella/zoster, yellow fever, rabies, BCG, and 
typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.  
• Systemic glucocorticoids for any purpose other than to modulate symptoms from an event of clinical interest of suspected immunologic etiology.  The use of physiologic doses of corticosteroids may be approved after consultation with the Sponsor. 
Participants who, in the assessment by [CONTACT_093], require the use of any of the aforementioned treatments for clinical management should be removed from the study.  All treatments that the Investigator considers necessary  for a participant’s welfare may be 
administered at the discretion of the Investigator in keepi[INVESTIGATOR_77981].   
Medications or vaccinations specifically prohibited in the exclusion criteria are not allowed during the ongoing study.  If there is a clinical indication for any medication or vaccination specifically prohibited during the study, discontinuation from study therapy or vaccination may be required.  The final decision on any supportive therapy or vaccination rests w ith the 
investigator and/or the participant's primary physician.  However, the decision to continue the participant on study treatment requires the mutual agreement of the investigator, the Sponsor and the participant.  
There are no prohibited therapi[INVESTIGATOR_3927]- Treatment Follow -up Phase. 
8.5 Rescue Medications & Supportive Care  
Participants should receive appropriate supportive care measures as deemed necessary by [CONTACT_12707].  Suggested supportive care measures for the management of AEs with potential immunologic etiology are outlined along with the dose modification guidelines in Section 7.2.2 [Table 5].  Where appropriate, these guidelines include the use of oral or IV treatment with corticosteroids, as well as additional anti- inflammator y agents if symptoms do not 
improve with administration of corticosteroids.  Note that several courses of steroid tapering may be necessary as symptoms may worsen when the steroid dose is decreased.  For each disorder, attempts should be made to rule out other causes such as metastatic disease or bacterial or viral infection, which might require additional supportive care.  The treatment guidelines are intended to be applied when the Investigator determines the events to be related to pembrolizumab.  
8.6 Dose A djustments for Weight 
Ramucirumab dose will be adjusted if patient has > 10% change in weight from weight used to 
calculate previous dose. No weight based dose adjustment is required for pembrolizumab.  
PROTOCOL NUMBER: OSU -[ADDRESS_587111] repeat imaging every 6 weeks to assess response.  
9.1.2 Secondary Endpoints  
• Safety and tolerability  as measured by [CONTACT_20721]  
• Clinical benefit rate – CR+PR+SD  
• Survival – progression- free and overall  
9.1.3 Exploratory Endpoints (Correlative Studies) 
To characterize predictive immunologic biomarkers of response in tissue and peripheral blood  
• T cell recept or (TCR) immunosequencing in peripheral blood (before and after treatment) 
and tumor tissue (at baseline) with clinical response. 
• CyTOF  from peripheral blood and infiltrating immune cells in tissue at baseline and after 
treatment  
• Circulating VEGF in peripheral blood at baseline and after treatment with clinical response  
9.2 Sample Size Justification   
Response rate with single agent IO is around 10% and we would consider a response rate of at 
least 25% to be interesting for further study. The optimal two- stage design to test the null 
hypothesis that P ≤ 0.10 versus the alternative that P ≥ 0.[ADDRESS_587112] stage, the trial will be terminated if no patients 
respond. If the trial goes on to the second stage, an additional 21 patients will be included for a total of 34 patients studied. 
9.4 Analysis Plan 
9.4.1  Primary endpoint analysis:  
The primary study objective is to assess the overall response rate (ORR) of ramucirumab plus 
pembrolizumab. To do so, we will use Simon’s two- stage design.
[ADDRESS_587113] group. Response rate with single 
agent IO is around 10% and we would consider a response rate of at least 25% to be interesting for further study. The optimal two- stage design to test the null hypothesis that P ≤ 0.10 versus the 
alternative that P ≥  0.[ADDRESS_587114] stage, the trial will be terminated if 1 or fewer respond. If the trial goes on to the second stage, an additional 21 patients will be included for a total of 34 patients studied. If the 
PROTOCOL NUMBER: OSU -[ZIP_CODE]  
  
CONFIDENTIAL  
 total number responding is less than or equal to 5, the drug is rejected. This design has an expected 
sample size of 20.95 and a probability of early termination of 0.621.The sample size was calculated using PASS 16 and ass uming α = 0.10 with a desired power of 80%.  
Overall survival and progression-free survival as continuous time- to-
 event outcomes : All 
evaluable patients will be used for this analysis.  Kaplan- Meier curves will be used to estimate 
overall survival, measured from the date of study registration to the date of event (i.e., death) or the date of last follow -up if no event has occurred at their last evaluation. We will further 
consider Cox proportional hazards models to explore a limited set of confounding factors.  
 
9.4.2
 Analysis of secondary endpoints:  
Secondary objectives involve evaluating safety and tolerability and estimating PFS and overall 
survival. Descriptive statistics will be calculated for these outcomes and Kaplan -Meier curves will 
be calculated to estimate PFS and OS. Patients who have reached the end of the study but not 
progressed will be considered censored at the last documented date of contact. Estimates from this analysis will be used as preliminary data to inform future research . 
Overall response. All evaluable patients (i.e. eligible patients who have received at least one dose 
of the treatment) will be assessed in terms of their best response to therapy. Those who achieve a partial response (PR) or complete response (CR) will be considered responses and the overall response rate will be calculated as the number of PRs and CRs divided by [CONTACT_128773]. We will also perform analysis of disease control rate (CR + PR + SD). These estimates will be accompanie d by [CONTACT_459707].  
 Safety and Tolerability . F
 requency and severity of adverse events and tolerability of the regimen 
will be collected and summarized by [CONTACT_459708].  As per NCI CT CAE v  5.0, the term toxicity is defined as adverse events that are classified as either 
possibly, probably, or definitely related to study treatments. The maximum grade for each type of toxicity will be recorded for each patient, and frequency tables will be reviewed to determine toxicity patterns. In addition, we will review all adverse event data that is graded as 3, 4, or 5 and classified as either “unrelated” or “unlikely to be related” to study treatment in the event of an actual relationship developi[INVESTIGATOR_007]. The incidence of severe (grade 3+) adverse events or toxicities will be described. We will also assess tolerability of the regimens through assessing the number of patients who required dose modifications and/or dose delays. In addition, we will also capture the proportion of patients who go off treatment due to adverse reactions or even those who refuse further treatment for lesser toxicities that inhibit their willingness to continue participation on the trial. All patients who have received at least o ne dose of the therapeutic agent in this study will 
be evaluable for toxicity and tolerability. This is detailed in Table 7. 
  
PROTOCOL NUMBER: OSU -[ZIP_CODE]  
  
CONFIDENTIAL  
 Table 7: Evaluating Adverse Events 
V5.0 CTCAE 
Grading  Grade 1  Mild; asymptomatic or mid symptoms; clinical or diagnostic observations 
only; intervention not indicated.  
 
Grade 2  Moderate; minimal, local or noninvasive intervention indicated; limiting 
age-appropriate instrumental ADL.  
 Grade 3  Severe or medically significant but not immediately life-threatening; 
hospi[INVESTIGATOR_77991]; disabling; 
limiting self -care ADL.  
 Grade 4  Life threatening consequences; urgent intervention indicated.  
 Grade [ADDRESS_587115] that: 
 †Results in death ; or 
 †Is life threatening; or  places the participant, in the view of the investigator, at immediate 
risk of death from the event as it occurred (Note: This does not include an adverse event that, had it occurred in a more severe form, might have caused death.); or 
 †Results in a pers istent or significant disability/incapacity  (substantial disruption of one’s 
ability to conduct normal life functions); or 
 †Results in or prolongs an existing inpatient hospi[INVESTIGATOR_059]  (hospi[INVESTIGATOR_459681], regardless of length of stay, even if the hospi[INVESTIGATOR_2138] a precautionary measure for continued observation. (Note: Hospi[INVESTIGATOR_19358] a pre -existing condition that has not worsened is not a serious adverse 
event.  A pre-existing condition is a clinical condition that is diagnosed prior to the use of the investigational products and is documented in the patient’s medical history.); or 
 †Is a congenital anomaly/birth defect  (in offspring of participant taking the product 
regardless of time to diagnosis);or 
 Is a new cancer  (that is not a condition of the study)  (although not serious per ICH 
definition, is reportable to the Sponsor within 24 hours, to [COMPANY_006] within 2 working days and to Lilly within 15 days to meet certain local requirements); or  
 Is an overdose  (whether accidental or intentional).  Any adverse event associated with an 
overdose is considered a serious adverse event for collection purposes. An overdose t hat is 
not associated with an adverse event is considered a non -serious event of clinical interest and 
must be reported within 24 hours to the Sponsor and to [COMPANY_006] within 2 working days and to Lilly within 15 days. 
 Other important medical events  that may not result in death, not be life threatening, or not 
require hospi[INVESTIGATOR_3767] a serious adverse event when, based upon 
PROTOCOL NUMBER: OSU -[ZIP_CODE]  
  
CONFIDENTIAL  
 appropriate medical judgment, the event may jeopardize the participant and may require 
medical or surgical intervention to prevent one of the outcomes listed previously (designated 
above by a †). 
Duration  Record the start and stop dates of the adverse event. If less than 1 day, indicate the 
appropriate length of time and units 
Action taken  Did the adverse event  cause investigational agent to be discontinued?  
Relationship 
to Investigational Product  Did investigational agent cause the adverse event? The determination of the likelihood that 
investigational agent caused the adverse event will be provided by [CONTACT_19427] a qualified physician. The investigator’s signed/dated initials on the source document or worksheet that supports the causality noted on the AE form, ensures that a medically qualified assessment of causality was done. This initialed document must be retained for the required regulatory time frame. The criteria below are intended as reference guidelines to assist the investigator in assessing the likelihood of a relationship between the test drug and the adverse event based upon the availab le information.  
The following components are to be used to assess the relationship between investigational agent  and the AE ; the greater the correlation with the components and their 
respective elements (in number and/or intensity), the more likely investigational agent caused the adverse event (AE):  
 Exposure  Is there evidence that the participant was actually exposed to investigational 
agent  such as: reliable history, acceptable compliance assessment (pi[INVESTIGATOR_692], 
diary, etc.), expected pharmacologic effect, or measurement of drug/metabolite in bodily specimen? 
 Time 
Course  Did the AE follow in a reasonable temporal sequence from administration of 
investigational agent ?  
Is the time of onset of the AE compatible with a drug-induced effect (applies to trials with investigational medicinal product)?  
 Likely 
Cause  Is the AE not reasonably explained by [CONTACT_121283], other drug(s)/vaccine(s), or other host or environmental factors 
 
9.5 Analysis of Exploratory Endpoints - Correlative studies :  
Several correlative markers will be explored in this trial in relation to clinical outcomes of 
interest, and in particular in relation to the primary endpoint of response rate . Statistical analysis 
corresponding to the correlative studies will be descriptive and exploratory in nature.  
For immune cell subpopulation data by [CONTACT_4133], we will identify differences between the 
paired PBMC samples from the same patients.  TCR immunoSEQ data will be summarized for each patient for T -cell clonality difference, descriptive statistics and confidence interval will be 
obtained across patients . 
PROTOCOL NUMBER: OSU -[ZIP_CODE]  
  
CONFIDENTIAL  
  To study the association of immune cell subpopulations among blood and the tumor 
microenvir onment, we will use linear mixed -effects models for repeated measurements within 
patients. A bivariate plot will be used to describe the relationship between response rate and peak VEGF via ELISA over time. Results will be summarized using descriptive statistics (i.e. means, medians, standard deviations, 95% confidence intervals for continuous variables, and frequencies for discrete data). The limited sample will not provide sufficient power for formal hypothesis testing (except to detect very large differences in these markers), but the preliminary data will be used to explore potential relationships and differences using graphical analyses and quantitative summaries of these markers. These results and exploratory analyses will also be used in planning a future randomized study of this combination treatment regimen in this patient population. 
10. DATA MANAGEMENT  
10.[ADDRESS_587116] compliance, data collection, abstraction and entry, data reporting, regulatory monitoring, problem resolution and prioritization, and coordinate the activities of the protocol study team and coordination with the study statistician. The data collected for this study will be entered into a secure database (Clinical Research Database (CRDB) . Source documentation will be available to 
support the computerized patient record. The principal investigator [INVESTIGATOR_459682].  
10.[ADDRESS_587117] the study participant.  
11.1 Human Subjects Involvement and Characteristics:  
All patients who meet the all of the inclusion and none of the exclusion criteria will be eligible. Eligible p atients will be 18 years of age or older with a ECOG performance status ≤ [ADDRESS_587118]-feeding women are excluded from this study. This 
PROTOCOL NUMBER: OSU -[ADDRESS_587119] en are 
already accessed by a nationwide pediatric cancer research network. This statement is based on exclusion 4b of the NIH Policy and Guidelines on the Inclusion of Children as Participants in Research Involving Human Subjects. 
11.2 Consent process:  
All patients at the OSU Thoracic Oncology clinic who meet the inclusion criteria will be eligible. 
Participation in the trial is voluntary. All patients will be required to sign a statement of informed 
consent, which must conform to IRB guidelines.  
11.3 Possible Toxi cities/Side -Effects:  
There are risks associated with treatment as  described in Section 7; however, patients screened 
for enrollment will be deemed appropriate for treatment independent of this study.  
11.3.[ADDRESS_587120] of research only biopsies, research related testing/screening, study drugs , as well as 
correlative analyses will be covered by [CONTACT_286524].   11.3.[ADDRESS_587121] 
chemotherapy or chemo -immunotherapy may be treatment alternatives.  
11.3.4 Confidentiality  
Every effort will be made to maintain patient confidentiality. Rese arch and hospi[INVESTIGATOR_459683]. Patients’ names and any other identifying information will not be used in reports or publications resulting from this study. Other authorized agencies and appropriate internal personnel (eg. qualified monitors) and external personnel (e.g. qualified monitors from Lilly or [COMPANY_006] ), its authorized agents, the FDA, and/or other governmental agencies) may review patient 
records as required.  
11.3.[ADDRESS_587122] a 24-hour urgent care facility for outpatients. The PI [INVESTIGATOR_5768]- PI 
[INVESTIGATOR_459684].  
PROTOCOL NUMBER: OSU -[ZIP_CODE]  
  
CONFIDENTIAL  
 11.3.6 Monitoring of data to ensure safety 
This study is to be monitored by [CONTACT_459709] (DSMC). This incorporates an independent data and safety monitoring board established by [CONTACT_459710]. The analysis of safety will include all patients. Adverse events, including all toxic effects of treatment, will be tabulated individually, and summarized by [CONTACT_213773].  
11.3.[ADDRESS_587123] (IRB/PB).  
12. INFORMED CONSENT  
Consent must be documented by [CONTACT_2299] ’s dated signature [INVESTIGATOR_4388] [CONTACT_2299] ’s legally 
acceptable representative’s dated signature [INVESTIGATOR_2394] a consent form along with the dated signature [CONTACT_80110].  
A copy of the signed and dated consent form should be given to the participant  before 
participation in the trial.  
The initial informed consent form, any subsequent revised written informed consent form and 
any written information provided to the participant must receive the IRB/ERC’s approval/favorable opi[INVESTIGATOR_19349].  The participant  or his/her legally acceptable 
representative should be informed in a timely manner if new information becomes available that may be relevant to the participant ’s willingness to continue participation in the trial.  The 
communication of this information will be provided and documented via a revised consent form or addendum to the original consent form that captures the participant ’s dated signature [INVESTIGATOR_4388] [CONTACT_2416]’s legally acceptable representative’s dated signature.  
Specifics about a trial and the trial population will be added to the consent form template at the protocol level.   
The informed consent will adhere to IRB/ERC requirements, applicable laws and regulations and 
Sponsor requirements. 
 
13. REPORTING REQUIREMENTS  
13.1 Adverse Drug Reaction Reporting  
Toxicity will be scored using CTC AE Version 5.0 for toxicity and adverse event reporting.  A 
copy of the CTC Version 4.0 can be downloaded from the CTEP homepage (http://ctep.info.nih.gov).  All appropriate treatment areas have access to a copy of the CTC 
Version 4.0.  
PROTOCOL NUMBER: OSU -[ZIP_CODE]  
  
CONFIDENTIAL  
 13.2 Serious Adverse Event Reporting (SAE)  
An adverse event or suspected adverse reaction is considered “serious” if, in the view of either 
the investigator, it results in any of the following outcomes: 
• Death  
• A life -threatening adverse drug experience – any adverse experience that places the 
patient, in the view of the init ial reporter, at immediate risk of death from the adverse 
experience as it occurred. It does not include an adverse experience that had it occurred in a more severe form, might have caused death.  
• Inpatient hospi[INVESTIGATOR_11636]  
• A persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions.  
• A congenital anomaly/birth defect.  
Important medical events that may not result in death, be life -threatening, or require 
hospi[INVESTIGATOR_193900] a serious adverse drug experience when, based upon 
appropriate medical judgment, they may jeopardize the patient or subject and may require 
medical or surgical intervention to prevent one of the outcomes listed in this definition. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse (21 CFR 312.32). 
Important medical events as defined above, may also be considered serious adverse events. Any 
important medical event can and should be reported as an SAE if deemed appropriate by [CONTACT_079].  
All events occurring during the conduct of a protocol and meeting the definition of a SAE must be reported to the IRB within 10 days of the investigator’s or research staff member’s learning of the event. Events resulting in temporary or permanent interruption of study activities by [CONTACT_093], sponsor, or DSMB to avoid potential harm to subjects should be reported within [ADDRESS_587124] who has withdrawn from or completed study participation.  If changes to the research or consent process are proposed as a result of the event, or if additional information will be provided to current and/or past participants, an amendment request must also be submitted for IRB review  
Serious adverse events will be captured from the time the patient signs consent until [ADDRESS_587125] be recorded for each serious adverse event in the SAE report form:  
• A description of the AE in medical terms  
• The severity grade as assessed by [CONTACT_459711]- CTCAE Version 5.0 
PROTOCOL NUMBER: OSU -[ZIP_CODE]  
  
CONFIDENTIAL  
 • The date of becoming serious and the date of becoming known (if different) 
• The reason for seriousness 
• The outcome of the SAE at the time of the report 
• Information on administration of the study drug and chemotherapy and any action taken 
• Information on any treatment procedures necessary for the SAE, concomitant medications, 
relevant lab tests and relevant medical history  
If in any one subject the same SAE occurs on several occasions, then the SAE in question must be documented and assessed anew each time.  
The investigator is required to submit SAE Follow-up reports until the SAE has resolved or stabilized and all queries have been answered. 
 
13.3 Reporting to FDA:  
Serious adverse events will be forwarded to FDA by [CONTACT_459712] 21 CFR 
312.32. 
It is the responsibility of the PI [INVESTIGATOR_195697], Good Clinical Practices, the protocol guidelines, the Investigator’s guidelines, and Institutional Review Board policy. 
13.4 Reporting to the Drug Provider ( Lilly ) 
Responsibilities of the Principal Investig ator and Institution also include: 
 
• to comply with applicable laws, regulations and standards regarding Investigator’s and 
Institution’s obligations, as the sponsor of the Study, to collect and report adverse events 
to regulatory authorities, IRBs, Ethics Committees or other third parties.  In addition to 
the obligations set forth below, Investigator and Institution agree to provide Lilly with a 
copy of all information Investigator and/or Institution submit to regulators related to any adverse events for th e Study Drug that occur during the Study that Investigator and/or 
Institution have not otherwise provided Lilly;  
• to notify Lilly, sub-investigators, and the IRB of any problems involving risk to Study 
patients and report new safety information to IRBs in accordance with applicable 
requirements;  
 
• to notify Lilly within fifteen (15) business days  of Investigator and/or Institution receiving 
notification of any “serious” and/or “unexpected” adverse event experienced by a patient participating in the Study and receiving Study Drug that is possibly related, based on 
Investigator’s assessment, to the Study Drug.  For purposes of this requirement, “serious” means:  (1) death; (2) in- patient hospi[INVESTIGATOR_13266]; (3) life -
threatening; (4) pe rsistent or significant disability or incapacity; (5) congenital anomaly or 
birth defect; or (6) other serious events that may jeopardize the patient and may require medical or surgical intervention to prevent one of the other five listed outcomes.  Serious adverse events should be reported to Lilly using a CIOMS Form or other form acceptable to Lilly.  Investigator and Institution further agree to make available promptly to Lilly such 
PROTOCOL NUMBER: OSU -[ZIP_CODE]  
  
CONFIDENTIAL  
 records as may be necessary and pertinent for Lilly to further investiga te an adverse event 
in the Study that is possibly associated with the Study Drug; 
  
Lilly Adverse Event Reporting:  
• Local fax number: [PHONE_6871] 
Local telephone number:  [PHONE_9638] 
 
13.5 Reporting to the Drug Provider (Mer ck) 
An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure.  Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the [COMPANY_006]’s product, is also an adverse event.  
 Changes resulting from normal growth and development that do not vary significantly in frequency or severity from expected levels are not to be considered adverse events.  Examples of this may include, but are not limited to, teething, typi[INVESTIGATOR_121254] a physiologically appropriate time.  [COMPANY_006] product includes any pharmaceutical product, biological product, device, diagnostic agent or protocol-specified procedure, whether investigational (including placebo or active comparator medication) or marketed, manufactured by, licensed by, provided by [CONTACT_199954]. 
 
Adverse events may occur during the course of the use of [COMPANY_006] product in clinical trials, or as prescribed in clinical practice, from overdose (whether accidental or intentional), from abuse and from withdrawal.  
 All AEs, SAEs and other reportable safety events that occur after the consent form is signed but before treatment allocation/randomization must be reported by [CONTACT_19449]-in or other run- in treatment, if the event cause the participant to be 
excluded from the study, or is the result of a protocol-specified intervention, including but not limited to washout or discontinuation of usual therapy, diet, or a procedure.   
• All AEs from the time of treatment allocation/randomization through [ADDRESS_587126] be reported by [CONTACT_093].  
• All AEs meeting serious criteria, from the time of treatment allocation/randomization 
through 90 days following cessation of study treatment, or 30 days following cessation of 
PROTOCOL NUMBER: OSU -[ADDRESS_587127] be reported by [CONTACT_093].  
• All pregnancies and exposure during breastfeeding, from the time of treatment allocation/randomization through [ADDRESS_587128] be reported by [CONTACT_093].  
• Additionally, any SAE brought to the attention of an investigator at any time outside of the time period specified above must be reported immediately by [CONTACT_459713]- related.  
 Investigators are not obligated to actively seek AE or SAE or other reportable safety events in former study participants. However, if the investigator learns of any SAE, including a death, at any time after a participant ha s been discharged from the study, and he/she considers the event to 
be reasonably related to the study treatment or study participation, the investigator must promptly notify [COMPANY_006]. 
 
13.5.1 Definition of an Overdose for This Protocol and Reporting of Overdose to the Sponsor and to [COMPANY_006]  
For purposes of this study, an overdose of pembrolizumab will be defined as any dose of 1,000 mg or greater (≥5 times the indicated dose).  No specific information is available on the treatment of overdose of pembrolizumab. In the event of overdose, the participant should be observed closely for signs of toxicity.  Appropriate supportive treatment should be provided if clinically indicated.  
 If an adverse event(s) is associated with (“results from”) the overdose of a Mer ck product, the 
adverse event(s) is reported as a serious adverse event, even if no other seriousness criteria are met. 
If a dose of [COMPANY_006]’s product meeting the protocol definition of overdose is taken without any associated clinical symptoms or abnormal laboratory results, the overdose is reported as a non-serious Event of Clinical Interest (ECI), using the terminology “accidental or intentional overdose without adverse effect.” All reports of overdose with and without an adverse event must be reported within 24 hours to the Sponsor and within 2 working days hours to [COMPANY_006] Global Safety. (Attn: Worldwide Product Safety; FAX [PHONE_1209])  
13.5.[ADDRESS_587129] feeding are not considered adverse 
events, it is the responsibility of investigators or their designees to report any pregnancy or lactation in a participant (spontaneously reported to them) that occurs during the study. Pregnancies and infant exposures during breastfeeding that occur after the consent form is signed but before treatment allocation/randomization must be reported by [CONTACT_191217], or are the result of a protocol- specified intervent ion, 
including but not limited to washout or discontinuation of usual therapy, diet, placebo treatment or a procedure.   
PROTOCOL NUMBER: OSU -[ZIP_CODE]  
  
CONFIDENTIAL  
  
Pregnancies and infant exposures during breastfeeding that occur from the time of treatment allocation/randomization through 120 days following cessation of Sponsor’s product, or [ADDRESS_587130] be followed to the complet ion/termination of the pregnancy. Pregnancy outcomes of spontaneous abortion, missed 
abortion, benign hydatidiform mole, blighted ovum, fetal death, intrauterine death, miscarriage and stillbirth must be reported as serious events (Important Medical Events). If the pregnancy continues to term, the outcome (health of infant) must also be reported. Such events must be reported within 24 hours to the Sponsor and within 2 working days to [COMPANY_006] Global Safety. (Attn: Worldwide Product Safety; FAX [PHONE_1209]) 
13.5.[ADDRESS_587131] that: • Results in death; • Is life threatening;  
• Result s in persistent or significant disability/incapacity; 
• Results in or prolongs an existing inpatient hospi[INVESTIGATOR_059]; • Is a congenital anomaly/birth defect; • Is another important medical event  
• Note: In addition to the above criteria, adverse events me eting either of the below criteria, 
although not serious per ICH definition, are reportable to the [COMPANY_006] in the same timeframe as SAEs to meet certain local requirements. Therefore, these events are considered serious by [CONTACT_131892]. • Is a new cancer (that is not a condition of the study); 
• Is associated with an overdose.  For the time period beginning when the consent form is signed until treatment allocation/randomization, any serious adverse event, or follow up to a serious adverse event, including death due to any cause that occurs to any participant must be reported within 24 hours to the Sponsor and within 2 working days to [COMPANY_006] Global Safety if it causes the participant to be excluded from the trial, or is the result of a protocol-specified intervention, including but not limited to washout or discontinuation of usual therapy, diet, placebo treatment or a procedure. For the time period beginning at treatment allocation/randomization through [ADDRESS_587132] be reported immediately to [COMPANY_006] Global Safety.  
PROTOCOL NUMBER: OSU -[ADDRESS_587133] be followed up for outcome. SAE reports and any other relevant safety information are to be forwarded to the [COMPANY_006] Global Safety facsimile number:  +1 -[PHONE_1209] 
 A copy of all 15 Day Reports and Annual Progress Reports is submitted as required by [CONTACT_8415], European Union (EU), Pharmaceutical and Medical Devices agency (PMDA) or other local regulators. Investigators will cross reference this submission according to local regulations to the [COMPANY_006] Investigational Compound Number (IND, CSA, etc.) at the time of submission.  Additionally investigators will submit a copy of these reports to [COMPANY_006] & Co., Inc. (Attn: Worldwide Product Safety; FAX [PHONE_1209]) at the time of submission to FDA.  
13.5.[ADDRESS_587134] 
(ECI) and must be reported within 2 working days to [COMPANY_006] Global Safety. (Attn: Worldwide 
Product Safety; FAX [PHONE_1209]).  For the time period beginning when the consent form is signed until treatment allocation/randomization, any ECI, or follow up to an ECI, that occurs to any participant must be reported within 2 working days to [COMPANY_006] Global Safety if it causes the participant to be excluded from the trial, or is the result of a protocol-specified intervention, including but not limited to washout or discontinuation of usual therapy, diet, placebo treatment or a procedure. For the time period beginning at treatment allocation/randomization through [ADDRESS_587135] for this trial include: 1.  an overdose of [COMPANY_006] product, as defined in Section 13.5.[ADDRESS_587136] of protocol-specified laboratory testing or unscheduled laboratory testing.* *Note:  These criteria are based upon available regulatory guidance documents. The purpose of the criteria is to specify a threshold of abnormal hepatic tests that may require an additional evaluation for an underlying etiology.  
13.6 Sponsor Responsibility f or Reporting Adverse Events  
All Adverse Events will be reported to regulatory authorities, IRB/IECs and investigators in 
accordance with all applicable global laws and regulations.  
  
PROTOCOL NUMBER: OSU -[ZIP_CODE]  
  
CONFIDENTIAL  
 14. REFERENCES  
 
1. Yang, J.C., et al., Afatinib versus cisplatin -based chemotherapy for EGFR mutation-
positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall 
survival data from two randomised, phase 3 trials. Lancet Oncol, 2015. 16(2): p. 141-51. 
2. Zhou, C., et al., Erlotinib versus chemotherapy as first- line treatment for patients with 
advanced EGFR mutation-positive non- small -cell lung cancer (OPTIMAL, CTONG-
0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol, 2011. 12(8): p. 735-42. 
3. Zhou, F., X. Chen, and C. Zhou, Epi[INVESTIGATOR_459685] -type lung cancer: when there is a target, there is a 
targeted drug. J Clin Oncol, 2015. 33(5): p. 523-4. 
4. Soria, J.C., et al., Osimertinib in Untreated EGFR -Mutated Advanced Non-Small- Cell 
Lung Cancer. N Engl J Med, 2018. 378(2): p. 113-125. 
5. Mazieres, J., et al., Efficacy of immune -checkpoint inhibitors (ICI) in non- small cell lung 
cancer (NSCLC) patients harboring activating molecular alterations (ImmunoTarget). Journal of Clinical Oncology, 2018. 36(15).  
6. Yang, Z., et al., Investigating Novel Resistance Mechanisms to Third-Generation EGFR 
Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients. Clin Cancer Res, 2018. 24 (13): p. 3097-3107. 
7. Reinmuth, N., et al., Correlation of EGFR mutations with chromosomal alterations and 
expression of EGFR, ErbB3 and VEGF in tumor samples of lung adenocarcinoma patients. Lung Cancer, 2008. 62(2): p. 193-201. 
8. Hegde,  P.S., J.J. Wallin, and C. Mancao, Predictive markers of anti -VEGF and emerging 
role of angiogenesis inhibitors as immunotherapeutics. Semin Cancer Biol, 2018. 52(Pt 2): p. 117-124. 
9. Gabrilovich, D.I., et al., Production of vascular endothelial growth factor by [CONTACT_459714]. Nat Med, 1996. 2(10): p. 1096-103. 
10. Oyama, T., et al., Vascular endothelial growth factor affects dendritic cell maturation 
through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells.  J Immunol, 1998. 160(3): p. 1224-32. 
11. Voron, T., et al., VEGF -A modulates expression of inhibitory checkpoints on CD8+ T 
cells in tumors.  J Exp Med, 2015. 212(2): p. 139-48. 
12. Ko, J.S., et al., Sunitinib mediates reversal of myeloid-derived suppressor cell 
accumulation in renal cell carcinoma patients. Clin Cancer Res, 2009. 15 (6): p. 2148-57. 
13. Ziogas, A.C., et al., VEGF directly suppresses activation of T cells from ovarian cancer 
patients and healthy individuals via VEGF receptor Type 2. Int J Cancer, 2012. 130(4): p. 857-64. 
14. Tada, Y., et al., Targeting VEGFR2 with Ramucirumab strongly impacts effector/ 
activated regulatory T cells and CD8(+) T cells in the tumor microenvironment.  J 
Immunother Cancer, 2018. 6(1): p. 106. 
15. Reck, M., et al., Primary PFS and safety analyses of a randomized Phase III study of 
carboplatin plus paclitaxel plus /- bevacizumab, with or without atezolizumab in 1L non-squamous metastatic NSCLC (IMpower150). Oncology Research and Treatment, 2018. 41: p. 187-187. 
PROTOCOL NUMBER: OSU -[ADDRESS_587137]-Line Treatment of Metastatic Nonsquamous 
NSCLC.  N Engl J Med, 2018. 378(24): p. 2288-2301. 
17. Cappuzzo, F., et al., LBA53IMpower130: Progression-free survival (PFS) and safety 
analysis from a randomised phase III study of carboplatin + nab- paclitaxel (CnP) with 
or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous 
NSCLC.  Annals of Oncology, 2018. 29(suppl_8): p. mdy424.065-mdy424.065. 
18. Disis, M.L., Immune regulation of cancer. J Clin Oncol, 2010. 28(29): p. 4531-8. 19. Dudley, M.E., et al., Adoptive cell transfer therapy following non-myeloablative but 
lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol, 2005. 23(10): p. 2346-57. 
20. Hunder, N.N., et al., Treatment of metastatic melanoma with autologous CD4+ T cells 
against NY- ESO-1. N Engl J Med, 2008. 358(25): p. 2698-703. 
21. Greenwald, R.J., G.J. Freeman, and A.H. Sharpe, The B7 family revisited.  Annu Rev 
Immunol, 2005. 23: p. 515-48. 
22. Okazaki, T., et al., PD -1 immunoreceptor inhibits B cell receptor-mediated signaling by 
[CONTACT_13223] 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci U S A, 2001. 98(24): p. [ZIP_CODE]-71. 
23. Chemnitz, J.M., et al., SHP -1 and SHP-2 associate with immunoreceptor tyrosine-based 
switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation pr events T cell activation.  J Immunol, 2004. 173(2): p. 945-54. 
24. Sheppard, K.A., et al., PD -1 inhibits T-cell receptor induced phosphorylation of the 
ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett, 2004. 574(1 -3): p. 37-41. 
25. Riley, J.L., PD -1 signaling in primary T cells. Immunol Rev, 2009. 229(1): p. 114-25. 
26. Parry, R.V., et al., CTLA -[ADDRESS_587138] 
mechanisms. Mol Cell Biol, 2005. 25(21): p. 9543-53. 
27. Francisco, L.M., P.T. Sage, and A.H. Sharpe, The PD -[ADDRESS_587139] in tolerance and 
autoimmunity. Immunol Rev, 2010. 236: p. 219-42. 
28. Garon, E.B., et al., Ramucirumab plus docetaxel versus placebo plus docetaxel for 
second -line treatment of stage IV non- small -cell lung cancer after disease progression on 
platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet, 2014. 384(9944): p. 665-73. 
29. Paz-Ares, L.G., et al., Treatment outcomes by [CONTACT_459715]: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer. Lung Cancer, 2017. 112: p. 126-133. 
30. Reck, M., et al., Pembrolizumab versus Chemotherapy for PD- L1-Positive Non -Small-
Cell Lung Cancer. N Engl J Med, 2016. 375(19): p. 1823-1833. 
31. Gandhi, L., et al., Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung 
Cancer.  N Engl J Med, 2018. 
32. Garon, E.B., et al., Pembrolizumab for the treatment of non- small -cell lung cancer.  N 
Engl J Med, 2015. 372(21): p. 2018-28. 
33. Wu, Y.L., et al., First -line erlotinib versus gemcitabine/cisplatin in patients with 
advanced EGFR mutation-positive non- small -cell lung cancer: analyses from the phase 
III, randomized, open-label, ENSURE study. Ann Oncol, 2015. 26(9): p. 1883-9. 
34. Sequist, L.V., et al., First -line gefitinib in patients with advanced non- small -cell lung 
cancer harboring somatic EGFR mutations. J Clin Oncol, 2008. 26(15): p. 2442-9. 
PROTOCOL NUMBER: OSU -[ADDRESS_587140], L.V., et al., Phase III study of afatinib or cisplatin plus pemetrexed in pati ents 
with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol, 2013. 31(27): 
p. 3327-34. 
36. Yu, H.A., et al., Analysis of tumor specimens at the time of acquired resistance to EGFR-
TKI therapy in 155 patients with EGFR-mutant lung cancers. Cl in Cancer Res, 2013. 
19(8): p. 2240-7. 
37. Ramalingam, S.S., et al., Osimertinib As First -Line Treatment of EGFR Mutation -
Positive Advanced Non- Small -Cell Lung Cancer. J Clin Oncol, 2018. 36(9): p. 841-849. 
38. Thress, K.S., et al., Acquired EGFR C797S mutation mediates resistance to AZD9291 in 
non-small cell lung cancer harboring EGFR T790M. Nat Med, 2015. 21(6): p. 560-2. 
39. Chen, K., et al., Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired 
Resistance to Osimertinib in Advanced NSCLC. J T horac Oncol, 2017. 12(6): p. e65-e68. 
40. Kim, T.M., et al., Mechanisms of Acquired Resistance to AZD9291: A Mutation-
Selective, Irreversible EGFR Inhibitor.  J Thorac Oncol, 2015. 10(12): p. 1736-44. 
41. Planchard, D., et al., EGFR-independent mechanisms of acquired resistance to AZD9291 
in EGFR T790M-positive NSCLC patients. Ann Oncol, 2015. 26(10): p. 2073-8. 
42. Peters, S., et al., Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for 
Patients With Programmed Death-Ligand 1- Selected Adva nced Non- Small -Cell Lung 
Cancer (BIRCH).  J Clin Oncol, 2017. 35(24): p. 2781-2789. 
43. Fehrenbacher, L., et al., Atezolizumab versus docetaxel for patients with previously 
treated non- small -cell lung cancer (POPLAR): a multicentre, open-label, phase 2 
randomised controlled trial. Lancet, 2016. 387([ZIP_CODE]): p. 1837-46. 
44. Rittmeyer, A., et al., Atezolizumab versus docetaxel in patients with previously treated 
non-small -cell lung cancer (OAK): a phase 3, open-label, multicentre randomised 
controlled trial.  Lancet, 2017. 389([ZIP_CODE]): p. 255-265. 
45. Herbst, R.S., et al., A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in 
patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a results. Journal of Clinical Oncology, 2016. 34(15).  
46. Seymour, L., et al., iRECIST: guidelines for response criteria for use in trials testing 
immunotherapeutics. Lancet Oncol, 2017. 18(3): p. e143-e152. 
 
  
PROTOCOL NUMBER: OSU -[ADDRESS_587141] 1.1 will be used as the primary measure for assessment of tumor response, date of disease 
progression, and as a basis for all protocol guidelines related to disease status (eg, discontinuation of study treatment).  Although RECI ST 1.[ADDRESS_587142] RESPONSE on study classified as outlined below: 
Complete Response (CR)  
Disappearance of all target lesions. Any pathological lymph nodes (whether target or non target) must have reduction in the short axis to <10mm. 
Partial Response (PR)  
At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline 
sum LD.  
Stable Disease (SD)  
Steady state of disease.  Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. 
Progressive Disease (PD)  
At least a 20% increase in the sum of diameters of measured lesions taking as references the 
smallest sum of diameters recorded since the treatment started.  In addition to the relative increase 
of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.  Appearance of one or more new lesions will also constitute progressive disease.  
Response Duration  
Response duration will be measured from the time measurement criteria for CR/PR (whichever is 
first recorded) are first met until the first da te that recurrent or progressive disease is objectively 
documented, taking as reference the smallest measurements recorded since the treatment started.  
Stable Disease Duration  
Stable disease duration will be measured from the time of start of therapy until the criteria for progression are met, taking as reference the smallest measurements recorded since the treatment started.  
PROTOCOL NUMBER: OSU -[ZIP_CODE]  
  
CONFIDENTIAL  
 APPENDIX 2: DESCRIPTION OF THE IRECIST PROCESS FOR ASSESSMENT OF 
DISEASE PROGRESSION 
Assessment at Screening and Prior to RECIST 1.[ADDRESS_587143] 1.1 the Investigator will 
decide whether to continue a participant on study treatment until repeat imaging is obtained (using iRECIST for participant management (see Table 1 and Figure 1).  This decision by [CONTACT_246136]’s overall clinical condition. 
Clinical stability is defined as the following:  
• Absence of symptoms and signs indicating clinically significant progression of disease 
• No decline in ECOG performance status  
• No requirements for intensified management, including increased analgesia, radiation, or 
other palliative care  
Any participant deemed clinically unstable should be discontinued from study treatment at site-assessed first radiologic evidence of PD, and is not required to have repeat tumor imaging for confirmation of PD by [CONTACT_34452] T. 
If the Investigator decides to continue treatment, the participant may continue to receive study treatment and the tumor assessment should be repeated [ADDRESS_587144] 1.1, 
including: 
• Increase in the sum of diameters of target lesion(s) identified at baseline to ≥  20% and 
≥ 5 mm from nadir  
o Please note: the iRECIST  publication uses the terminology “sum of measurements”, 
but “sum of diameters” will be used in this protocol, consistent with the original RECIST 1.1 terminology. 
• Unequivocal progression of non- target lesion(s) identified at baseline  
• Development of new lesion(s) 
iRECIST defines new response categories, including iUPD (unconfirmed progressive disease) and iCPD (confirmed progressive disease).  For purposes of iRECIST assessment, the first visit showing progression according to RECIST 1.1 will be assigned a visit (overall) response of iUPD, regardless of which factors caused the progression. 
PROTOCOL NUMBER: OSU -[ADDRESS_587145] 1.1.  From measurable new lesions, up to 5 lesions total (up to 2 per organ), may be selected as New Lesions – Target.  The sum of diameters of these lesions will be ca lculated, and kept distinct from the sum of diameters for 
target lesions at baseline.  All other new lesions will be followed qualitatively as New Lesions – Non-target.  
Assessment at the Confirmatory Imaging  
On the confirmatory imaging, the participant will be classified as progression confirmed (with an overall response of iCPD), or as showing persistent unconfirmed progression (with an overall response of iUPD), or as showing disease stability or response (iSD/iPR/iCR). 
Confirmation of Progression Progres sion is considered confirmed, and the overall response will be iCPD, if ANY of the 
following occurs: 
• Any of the factors that were the basis for the initial iUPD show worsening 
o For target lesions, worsening is a further increase in the sum of diameters of ≥  5 mm, 
compared to any prior iUPD time point 
o For non -target lesions, worsening is any significant growth in lesions overall, compared 
to a prior iUPD time point; this does not have to meet the “unequivocal” standard of 
RECIST 1.1  
o For new lesions, worsening is any of these: 
 An increase in the new lesion sum of diameters by ≥  5 mm from a prior iUPD time 
point  
 Visible growth of new non- target lesions  
 The appearance of additional new lesions 
• Any new factor appears that would have triggered PD by [CONTACT_393] 1.1 
Persistent iUPD  
Progression is considered not confirmed, and the overall response remains iUPD, if: 
• None of the progression-confirming factors identified above occurs AND 
• The target lesion sum of diameters (initial target lesions) remains above the initial PD 
threshold (by [CONTACT_393] 1.1) 
Additional imaging for confirmation should be scheduled 4 to 8 weeks from the scan on which 
iUPD is seen.  This may correspond to the next visit in the original visit schedule.  The 
PROTOCOL NUMBER: OSU -[ZIP_CODE]  
  
CONFIDENTIAL  
 assessment of the subsequent confirmation scan proceeds in an identical manner, with possible 
outcomes of iCPD, iUPD, and iSD/iPR/iCR. 
Resolution of iUPD Progression is considered not confirmed, and the overall response becomes iSD/iPR/iCR, if: 
• None of the progression-confirming factors identified above occurs, AND 
• The target lesion sum of diameters (initial target lesions) is not above the initial PD 
thres hold.  
The response is classified as iSD or iPR (depending on the sum of diameters of the target lesions), or iCR if all lesions resolve.  
In this case, the initial iUPD is considered to be pseudo-progression, and the level of suspi[INVESTIGATOR_19367] “reset”.  This means that the next visit that shows radiographic progression, whenever it occurs, is again classified as iUPD by [CONTACT_19393], and the confirmation process is repeated before a response of iCPD can be assigned.  
Management Following the Confirmatory Imaging 
If repeat imaging does not confirm PD per iRECIST, as assessed by [CONTACT_737], and the 
participant continues to be clinically stable, study treatment may continue and follow the regular imaging schedule.  If PD is confirmed, participants will be discontinued from study treatment. 
NOTE: If a participant has confirmed radiographic progression (iCPD) as defined above, but the 
participant is achieving a clinically meaningful benefit, an exception to continue study treatment may be considered.  In this case, if study treatment is continued, tumor imaging should continue to be performed following the intervals as outlined above. 
Detection of Progression at Visits After Pseudo -progression Resolves 
After resolution of pseudo-progression (ie, achievem ent of iSD/iPR/iCR), iUPD is indicated by 
[CONTACT_19518]: 
• Target lesions  
o Sum of diameters reaches the PD threshold (≥  20% and ≥  5 mm increase from nadir) 
either for the first time, or after resolution of previous pseudo- progression.  The nadir  
is always the smallest sum of diameters seen during the entire trial, either before or 
after an instance of pseudo -progression. 
• Non-target lesions  
o If non -target lesions have never shown unequivocal progression, their doing so for the 
first time results in iUPD.  
PROTOCOL NUMBER: OSU -[ZIP_CODE]  
  
CONFIDENTIAL  
 o If non -target lesions had shown previous unequivocal progression, and this progression 
has not resolved, iUPD results from any significant further growth of non- target lesions, 
taken as a whole.  
• New lesions  
o New lesions appear for the first time  
o Additional new lesions appear 
o Previously identified new target lesions show an increase of ≥  5 mm in the new lesion 
sum of diameters, from the nadir val ue of that sum  
o Previously identified non-target lesions show any significant growth 
If any of the events above occur, the overall response for that visit is iUPD, and the iUPD 
evaluation process (see Assessment at the Confirmatory Imaging above) is repeated.  Progression must be confirmed before iCPD can occur. 
The decision process is identical to the iUPD confirmation process for the initial PD, except in 
one respect. If new lesions occurred at a prior instance of iUPD, and at the confirmatory scan the burden of new lesions has increased from its smallest value (for new target lesions, their sum of diameters is ≥5 mm increased from its nadir), then iUPD cannot resolve to iSD or iPR. It will remain iUPD until either a decrease in the new lesion burden allows  resolution to iSD or iPR, or 
until a confirmatory factor causes iCPD.  
Additional details about iRECIST are provided in the iRECIST publication .[46] 
 
PROTOCOL NUMBER: OSU -[ZIP_CODE]  
  
CONFIDENTIAL  
 APPENDIX 3: EASTERN COOPERAT IVE ONCOLOGY GROUP (ECOG) 
PERFORMANCE STATUS SCALE ASSESSMENT  
ECOG Performance Status Scale  
Grade  Descriptions  
0 Normal activity.  Fully active, able to carry on all pre -
disease performance without restriction.  
1 Symptoms, but ambulatory.  Restricted in physically 
strenuous activity, but ambulatory and able to carry out work 
of a light or sedentary nature ( e.g., light housework, office 
work).  
2 In bed <50% of the time.  Ambulatory and capable of all self-care, but unable to carry out any work activities.  Up 
and about more than 50% of waking hr. 
3 In bed >50% of the time.  Capable of only limited self- care, 
confined to bed or chair more than 50% of waking hr. 
4 100% bedridden.  Completely disabled.  Cannot carry on any self-care.  Totally confined to bed or chair. 
5 Dead.  
Oken MM, Creech RH, Tormey  DC, et al. Toxicity and response criteria of 
the Eastern Cooperative Oncology Group. Am J Clin Oncol  1982;5:649-
655 
   
PROTOCOL NUMBER: OSU -[ZIP_CODE]  
  
CONFIDENTIAL  
 APPENDIX 4: COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS V5.0 
(CTCAE)  
The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 will be utilized for adverse event reporting. (http://ctep.cancer.gov/reporting/ctc.html ) 
  
PROTOCOL NUMBER: OSU -[ZIP_CODE]  
  
CONFIDENTIAL  
 APPENDIX 5: CONTRACEPTIVE GUIDANCE AND PREGNANCY TESTING  
Woman of Childbearing Potential (WOCBP) 
A woman is considered fertile following menarche and until becoming post-menopausal unless 
permanently sterile (see below)  
Women in the following categories are not considered WOCBP: 
• Premenarchal  
• Premenopausal female with 1 of the following: 
o Documented hysterectomy  
o Documented bilateral salpi[INVESTIGATOR_1656]  
o Documented bilateral oophorectomy 
Note:  Documentation can come from the site personnel’s review of the participant’s medical 
records, medical examination, or medical history interview. 
• Postmenopausal female  
o A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause.  
o A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy (HRT). H owever, in the absence 
of 12 months of amenorrhea, confirmation with two FSH measurements in the postmenopausal range is required.  
• F
emales on HRT and whose menopausal status is in doubt will be required to use one of 
the non-hormonal highly effective contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before study enrollment. 
Contraception Requirements  
Ma
le Participants:  
Male participants with female partners of childbearing potential are eligible to participate if they agree to one of the following during the protocol defined time frame:  
• Be abstinent from penile-vaginal intercourse as their usual and preferred lifestyle (abstinent 
on a long term and persistent basis) and agree to remain abstinent 
• Use a male condom plus partner use of a contraceptive method with a failure rate of <1% per 
year when having penile-vaginal intercourse with a woman of childbearing potent ial who  is 
not currently pregnant. 
o N
ote: Men with a pregnant or breastfeeding partner must agree to remain abstinent from 
penile-vaginal intercourse or use a male condom during each epi[INVESTIGATOR_117492]. 
 
Female participants:  
 
PROTOCOL NUMBER: OSU -[ZIP_CODE]  
  
CONFIDENTIAL  
 Female Participants:  
Female participants of childbearing potential are eligible to participate if they  agree to use a 
highly effective method of contraception consistently and correctly as described in Table 8 
during the protocol- defined time frame .  
 
Table 8 : Highly Effective Contraception Methods 
Highly Effective Contraceptive Methods That Are User Dependent a  
Failure rate of <1% per year when used consistently and correctly.  
• Combined (estrogen - and progestogen - containing ) hormonal contraception b, c 
• Oral  
• Intravaginal  
• Transdermal  
• Injectable  
Progestogen -only hormonal contraception b, c 
• Oral  
• Injectable  
Highly Effective Methods That Have Low User Dependency  
Failure rate of <1% per year when used consistently and correctly.  
• Progestogen- only contraceptive implant b, c  
• Intrauterine hormone- releasing system (IUS)  b  
• Intrauterine device (IUD)  
• Bilateral tub al occlusion  
 
Vasectomized partner  
A vasectomized partner is a highly effective contraception method provided that the partner is 
the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If 
not, an additional highly effective method of contraception should be u sed.  
   Sexual abstinence  
Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment. The reliability of sexual abstinence needs to be evaluated in relati on to the duration of the 
study and the preferred and usual lifestyle of the participant.)  
Notes:  
Use should be consistent with local regulations regarding the use of contraceptive methods for 
participants of clinical studies.  
 a) Typi[INVESTIGATOR_122955] -use failure rates (i.e. when used consistently 
and correctly).  
b) If hormonal contraception efficacy is potentially decreased due to interaction with study 
treatment, condoms must be used in addition to the hormonal contraception during the 
treatment period and for at least [ADDRESS_587146] dose of study treatment . 
PROTOCOL NUMBER: OSU -[ZIP_CODE]  
  
CONFIDENTIAL  
 c) If locally required, in accordance with Clinical Trial Facilitation Group (CTFG) guidelines, 
acceptable hormonal contraceptives are limited to those which inhibit ovulation.  
 
Pregnancy Testing  
WOCBP should only be included after a negative highly sensitive urine or serum pregnancy test.  
Following initiation of treatment, pregnancy testing will be performed whenever an expected 
menstrual cycle is missed or when pregnancy is otherwise suspected; at the time points specified in the Schedule of Activities, and as required locally. 
Pregnancy testing will be performed whenever an expected menstrual cycle is missed or when 
pregnancy is otherwise suspected. 
 
 
PROTOCOL NUMBER: OSU -[ZIP_CODE]  
  
CONFIDENTIAL  
  
 
 
  